

**Table 5      Summary of Hematology**

Table 5 Summary of Hematology

Key Page**Measurement Descriptions**Headings Used

WBC

RBC

HGB

HCT

MCV

MCH

MCHC

RDW

#RET

#NEUT

%NEUT

#LYMP

%LYMP

#MONO

%MONO

#EOS

%EOS

#BASO

%BASO

PLT

MPV

Description

Leukocyte count

Erythrocyte count

Hemoglobin

Hematocrit

Mean Corpuscular Volume

Mean Corpuscular Hemoglobin

Mean Corpuscular Hemoglobin Conc.

RBC Distribution Width

Reticulocytes, absolute

Neutrophils, absolute

Neutrophils, percent

Lymphocytes, absolute

Lymphocytes, percent

Monocytes, absolute

Monocytes, percent

Eosinophils, absolute

Eosinophils, percent

Basophils, absolute

Basophils, percent

Platelet Count

Mean Platelet Volume

Table 5 Summary of Hematology-Pretest and Dosing Phase

Day(s) Relative to Start Date

Sex: Male		WBC	WBC	WBC	WBC	WBC	WBC	RBC	RBC	RBC	RBC	RBC	RBC
		(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>6</sup> /μL)	(x10 <sup>6</sup> /μL)	(x10 <sup>6</sup> /μL)	(x10 <sup>6</sup> /μL)	(x10 <sup>6</sup> /μL)	(x10 <sup>6</sup> /μL)
		[a]	[a1]	[a1]	[a1]	[a1]	[a1]	[a1]	[a1]	[a1]	[a1]	[a1]	[a1]
		-11	-6	53	87	123	179	-11	-6	53	87	123	179
1	Mean	10.80	11.39	10.28	9.64	7.88	9.89	5.71	5.50	5.85	5.75	5.80	5.65
0	SD	4.25	2.95	2.73	4.09	0.87	4.00	0.30	0.27	0.23	0.24	0.34	0.29
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	9.55	10.87	9.58	11.18	8.64	8.35	5.63	5.49	5.98	5.75	5.85	5.63
5	SD	3.10	4.29	2.77	4.12	3.67	2.31	0.62	0.57	0.36	0.42	0.35	0.45
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-11.52	-4.57	-6.84	15.99	9.53	-15.55	-1.40	-0.21	2.28	-0.14	0.83	-0.47
3	Mean	8.70	9.89	9.32	7.92	9.29	7.37	5.75	5.43	5.95	5.59	5.69	5.79
25	SD	1.32	1.90	1.15	1.49	1.45	1.76	0.47	0.41	0.40	0.70	0.44	0.30
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-19.45	-13.16	-9.31	-17.87	17.89	-25.51	0.64	-1.36	1.74	-2.87	-1.81	2.45
4	Mean	8.51	11.24	11.71	10.16	10.07	7.59	5.79	5.70	5.99	5.57	5.85	5.64
100	SD	1.99	3.30	5.44	5.82	4.73	1.97	0.11	0.26	0.33	0.75	0.79	0.64
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-21.21	-1.27	13.89	5.38	27.74	-23.31	1.34	3.58	2.40	-3.16	0.80	-0.18

[a] - Anova & Dunnett(Log)

[a1] - Anova & Dunnett

Table 5 Summary of Hematology-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Male		HGB	HGB	HGB	HGB	HGB	HGB	HCT	HCT	HCT	HCT	HCT	HCT
		(g/dL)	(g/dL)	(g/dL)	(g/dL)	(g/dL)	(g/dL)	(%)	(%)	(%)	(%)	(%)	(%)
		[a]	[a1]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]
		-11	-6	53	87	123	179	-11	-6	53	87	123	179
1	Mean	13.2	12.6	13.5	13.2	13.6	13.3	43.3	42.4	44.6	43.5	43.3	43.0
0	SD	0.5	0.2	0.7	0.5	0.4	0.6	2.1	1.5	3.9	1.5	1.7	2.3
	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	12.6	12.3	13.2	12.7	13.2	12.7	41.5	41.1	42.9	41.5	42.2	41.2
5	SD	1.4	1.2	0.6	0.8	0.9	0.9	4.2	3.3	1.6	2.7	2.4	3.0
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-4.2	-2.5	-2.1	-4.0	-2.6	-4.5	-4.1	-3.0	-3.7	-4.6	-2.6	-4.3
3	Mean	13.7	12.9	14.0	13.1	13.7	13.8	43.9	42.1	44.8	42.2	43.3	44.2
25	SD	0.5	0.5	0.3	1.4	0.6	0.5	1.1	1.8	2.1	4.9	2.1	1.4
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	3.8	1.8	4.2	-0.4	1.2	4.3	1.5	-0.7	0.4	-2.9	0.1	2.7
4	Mean	13.3	13.1	13.6	12.6	13.5	13.0	42.8	42.9	43.8	41.5	43.8	42.6
100	SD	0.5	0.6	0.4	1.5	1.7	1.3	2.1	2.9	1.3	2.7	3.8	2.4
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	1.0	3.4	0.9	-4.6	-0.1	-2.1	-1.3	1.3	-1.8	-4.4	1.1	-0.9

[a] - Anova &amp; Dunnett

[a1] - Kruskal-Wallis &amp; Dunnett on Ranks

Table 5 Summary of Hematology-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Male		MCV	MCV	MCV	MCV	MCV	MCV	MCH	MCH	MCH	MCH	MCH	MCH
		(fL)	(fL)	(fL)	(fL)	(fL)	(fL)	(pg)	(pg)	(pg)	(pg)	(pg)	(pg)
		[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]
		-11	-6	53	87	123	179	-11	-6	53	87	123	179
1	Mean	76.0	77.1	76.2	75.6	74.9	76.1	23.0	23.0	23.0	23.0	23.4	23.5
0	SD	3.9	3.6	4.5	3.7	3.7	3.4	0.7	0.9	0.6	0.8	0.7	0.9
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	74.0	75.1	72.0	72.3	72.3	73.3	22.4	22.5	22.1	22.1	22.6	22.6
5	SD	5.2	4.3	4.3	4.7	4.6	5.0	1.6	1.7	1.5	1.6	1.5	1.7
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-2.7	-2.6	-5.6	-4.3	-3.4	-3.7	-2.6	-2.2	-4.0	-3.8	-3.6	-3.9
3	Mean	76.8	77.7	75.4	75.6	76.3	76.3	23.9	23.8	23.7	23.6	24.2	23.9
25	SD	4.9	4.5	3.1	3.1	2.9	2.7	1.3	1.3	1.1	0.9	1.0	0.7
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	1.1	0.8	-1.1	0.1	1.9	0.3	3.6	3.4	2.7	2.8	3.1	1.6
4	Mean	73.9	75.3	73.3	75.3	75.4	76.0	23.0	23.0	22.7	22.6	23.2	23.1
100	SD	3.0	3.4	3.3	7.3	5.8	5.4	0.8	0.8	0.8	0.9	0.9	0.8
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-2.8	-2.4	-3.9	-0.4	0.7	-0.2	-0.3	-0.1	-1.3	-1.5	-0.9	-1.8

[a] - Anova &amp; Dunnett

Table 5 Summary of Hematology-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Male		MCHC	MCHC	MCHC	MCHC	MCHC	MCHC	RDW	RDW	RDW	RDW	RDW	RDW
		(g/dL)	(g/dL)	(g/dL)	(g/dL)	(g/dL)	(g/dL)	(%)	(%)	(%)	(%)	(%)	(%)
		[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]
		-11	-6	53	87	123	179	-11	-6	53	87	123	179
1	Mean	30.4	29.8	30.3	30.4	31.3	30.9	13.5	13.5	13.3	13.5	13.0	13.6
0	SD	0.7	0.7	1.1	0.9	0.9	0.6	0.6	0.5	0.3	0.5	0.7	0.5
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	30.3	29.9	30.7	30.5	31.3	30.8	14.1	13.8	13.3	13.7	12.8	14.0
5	SD	0.5	0.9	0.7	0.6	0.8	1.0	1.4	1.1	0.7	0.8	0.5	0.6
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-0.2	0.2	1.4	0.4	-0.2	-0.3	4.2	2.2	0.0	1.4	-1.5	2.4
3	Mean	31.1	30.6	31.4	31.2	31.7	31.3	13.8	13.5	12.8	13.7	12.8	13.6
25	SD	0.5	0.6	0.9	0.6	0.5	0.2	0.7	0.5	0.5	0.9	0.7	0.4
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	2.4	2.6	3.7	2.7	1.2	1.3	1.9	0.4	-3.1	1.6	-1.3	-0.5
4	Mean	31.1	30.5	31.1	30.2	30.9	30.4	13.7	13.6	13.1	13.5	12.8	13.6
100	SD	0.7	0.9	1.0	2.2	1.7	1.8	0.4	0.4	0.4	0.4	0.4	0.5
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	2.3	2.3	2.6	-0.6	-1.4	-1.6	1.1	1.2	-1.0	0.2	-1.5	-0.2

[a] - Anova &amp; Dunnett

Table 5 Summary of Hematology-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Male		#RET	#RET	#RET	#RET	#RET	#RET	#NEUT	#NEUT	#NEUT	#NEUT	#NEUT	#NEUT
		(x10 <sup>9</sup> /L)	(x10 <sup>9</sup> /L)	(x10 <sup>9</sup> /L)	(x10 <sup>9</sup> /L)	(x10 <sup>9</sup> /L)	(x10 <sup>9</sup> /L)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)
		[a]	[a1]	[a1]	[a1]	[a]	[a]	[a1]	[a1]	[a]	[a1]	[a]	[a]
		-11	-6	53	87	123	179	-11	-6	53	87	123	179
1	Mean	42.4	64.1	49.4	55.3	53.9	59.7	5.77	3.76	3.16	3.27	1.99	3.36
0	SD	18.2	26.2	14.0	17.0	21.9	15.5	2.73	1.63	2.45	2.71	0.69	2.67
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	99.0	93.4	44.5	58.5	46.1	57.5	4.19	3.13	2.29	4.60	2.12	1.66
5	SD	98.8	72.6	12.7	23.9	7.1	31.1	2.26	1.56	0.44	3.49	1.58	0.73
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	133.4	45.8	-10.1	5.9	-14.6	-3.7	-27.40	-16.75	-27.58	40.38	6.71	-50.70
3	Mean	58.0	68.3	38.7	76.5	55.9	48.2	4.72	3.66	3.25	2.39	3.31	1.51
25	SD	20.4	25.3	13.2	54.2	15.8	9.9	1.90	2.21	2.35	0.96	2.55	0.50
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	36.8	6.7	-21.7	38.5	3.7	-19.3	-18.31	-2.70	2.96	-27.09	66.78	-54.92
4	Mean	49.3	69.1	60.8	108.5	87.8	93.2	4.39	4.91	6.11	5.65	5.10	2.23
100	SD	17.1	36.8	28.2	126.5	93.6	111.2	2.30	2.90	5.43	5.56	4.81	1.08
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	16.2	7.9	23.0	96.3	62.9	56.1	-23.94	30.48	93.61	72.71	156.88	-33.71

[a] - Anova &amp; Dunnett(Log)

[a1] - Anova &amp; Dunnett

Table 5 Summary of Hematology-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Male		%NEUT	%NEUT	%NEUT	%NEUT	%NEUT	%NEUT	#LYMP	#LYMP	#LYMP	#LYMP	#LYMP	#LYMP
		(%)	(%)	(%)	(%)	(%)	(%)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)
		[a]	[a]	[a]	[a]	[a1]	[a]	[a]	[a]	[a]	[a]	[a]	[a]
		-11	-6	53	87	123	179	-11	-6	53	87	123	179
1	Mean	52.0	32.8	28.0	30.7	25.2	31.1	4.62	6.90	6.56	5.83	5.39	5.86
0	SD	7.0	8.0	16.1	12.8	8.3	14.6	1.45	2.00	1.43	2.12	0.87	2.10
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	42.6	29.2	24.4	37.5	22.9	20.7	4.89	7.03	6.67	6.02	6.06	6.15
5	SD	15.4	11.6	3.4	16.4	9.0	9.7	2.06	3.27	2.28	1.85	2.13	2.28
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-18.1	-11.0	-13.0	22.1	-9.0	-33.4	5.92	1.79	1.68	3.20	12.40	4.98
3	Mean	52.7	35.8	33.3	30.4	33.9	20.5	3.73	5.76	5.67	5.15	5.54	5.46
25	SD	18.0	19.3	19.5	12.0	21.2	4.0	1.07	1.87	1.47	1.29	1.88	1.23
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	1.3	9.2	18.8	-1.0	34.9	-34.0	-19.37	-16.59	-13.64	-11.70	2.81	-6.83
4	Mean	50.6	42.7	45.9	48.7	42.7	30.5	3.80	5.80	5.07	4.07	4.56	5.00
100	SD	18.9	15.9	23.3	22.3	24.5	12.8	1.73	2.18	1.60	1.66	1.58	2.03
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-2.7	30.1	63.7	58.8	69.6	-2.0	-17.71	-15.96	-22.71	-30.11	-15.40	-14.57

[a] - Anova &amp; Dunnett

[a1] - Anova &amp; Dunnett(Log)



Table 5 Summary of Hematology-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Male		%LYMP	%LYMP	%LYMP	%LYMP	%LYMP	%LYMP	#MONO	#MONO	#MONO	#MONO	#MONO	#MONO
		(%)	(%)	(%)	(%)	(%)	(%)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)
		[a]	[a]	[a]	[a]	[a]	[a1]	[a]	[a]	[a]	[a]	[a]	[a]
		-11	-6	53	87	123	179	-11	-6	53	87	123	179
1	Mean	44.2	60.7	66.3	63.3	68.4	61.6	0.24	0.36	0.28	0.28	0.28	0.34
0	SD	6.3	8.7	14.9	12.4	8.1	14.5	0.16	0.09	0.10	0.12	0.05	0.15
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	52.7	64.6	68.9	57.3	71.7	72.9	0.27	0.37	0.34	0.35	0.28	0.33
5	SD	14.9	11.4	4.3	16.0	8.5	10.1	0.10	0.18	0.12	0.15	0.12	0.11
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	19.3	6.5	4.0	-9.4	4.8	18.2	13.89	1.83	22.16	25.00	1.81	-2.99
3	Mean	44.4	59.4	62.2	64.8	61.4	74.3	0.16	0.29	0.24	0.26	0.29	0.22
25	SD	18.0	19.0	18.6	11.6	21.9	4.1	0.05	0.06	0.08	0.08	0.09	0.05
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	0.6	-2.1	-6.1	2.5	-10.3	20.6	-31.94	-20.18	-13.17	-8.33	4.22	-34.83
4	Mean	45.7	52.4	49.4	46.5	52.8	64.5	0.21	0.28	0.29	0.27	0.26	0.20
100	SD	18.2	15.8	22.5	21.2	23.5	13.0	0.07	0.07	0.11	0.10	0.10	0.05
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	3.5	-13.7	-25.5	-26.6	-22.9	4.7	-14.58	-22.02	5.39	-4.17	-6.63	-40.30

[a] - Anova &amp; Dunnett

[a1] - Kruskal-Wallis &amp; Dunnett on Ranks

Table 5 Summary of Hematology-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Male		%MONO	%MONO	%MONO	%MONO	%MONO	%MONO	#EOS	#EOS	#EOS	#EOS	#EOS	#EOS
		(%)	(%)	(%)	(%)	(%)	(%)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)
		[a]	[a]	[a]	[a1]	[a]	[a]	[a2]	[a]	[a]	[a]	[a2]	[a]
		-11	-6	53	87	123	179	-11	-6	53	87	123	179
1	Mean	2.2	3.3	2.7	2.9	3.5	3.4	0.08	0.22	0.17	0.18	0.15	0.25
0	SD	0.9	0.6	0.5	0.2	0.4	1.0	0.05	0.20	0.13	0.19	0.16	0.22
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	2.9	3.3	3.6	3.2	3.3	3.9	0.10	0.20	0.16	0.12	0.07	0.14
5	SD	0.8	1.3	1.1	1.2	1.0	1.2	0.12	0.21	0.12	0.06	0.05	0.11
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	28.4	2.6	36.5	9.7	-3.8	14.8	14.00	-12.03	-5.94	-30.48	-51.69	-43.24
3	Mean	1.9	3.0	2.6	3.2	3.1	3.0	0.04	0.10	0.09	0.06	0.05	0.14
25	SD	0.5	0.6	1.0	0.7	0.8	0.6	0.02	0.08	0.08	0.06	0.03	0.20
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-15.7	-8.2	-0.6	9.7	-9.6	-11.8	-52.00	-55.64	-44.55	-64.76	-67.42	-44.59
4	Mean	2.4	2.7	2.6	2.8	2.7	2.8	0.06	0.18	0.13	0.08	0.08	0.09
100	SD	0.6	0.8	0.3	0.6	0.4	0.7	0.02	0.08	0.09	0.05	0.04	0.04
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	6.7	-18.5	-3.1	-2.9	-23.6	-18.7	-34.00	-26.32	-22.77	-55.24	-46.07	-65.54

[a] - Anova & Dunnett  
[a1] - Kruskal-Wallis & Dunnett on Ranks  
[a2] - Anova & Dunnett(Log)

Table 5 Summary of Hematology-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Male		%EOS	%EOS	%EOS	%EOS	%EOS	%EOS	#BASO	#BASO	#BASO	#BASO	#BASO	#BASO
		(%)	(%)	(%)	(%)	(%)	(%)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)
		[a]	[a]	[a]	[a1]	[a]	[a]	[a]	[a2]	[a]	[a]	[a]	[a]
		-11	-6	53	87	123	179	-11	-6	53	87	123	179
1	Mean	0.9	2.1	1.8	2.2	1.9	3.0	0.03	0.04	0.03	0.02	0.02	0.04
0	SD	0.4	1.6	1.6	2.8	2.0	2.9	0.01	0.02	0.01	0.01	0.01	0.02
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	1.0	1.6	1.8	1.1	0.9	1.6	0.03	0.03	0.02	0.02	0.03	0.03
5	SD	0.8	1.0	1.3	0.5	0.6	0.9	0.02	0.03	0.01	0.01	0.02	0.01
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	11.8	-22.0	-4.5	-50.0	-52.6	-47.2	-6.25	-22.73	-26.67	0.00	14.29	-23.81
3	Mean	0.5	1.0	1.0	0.7	0.5	1.6	0.01	0.02	0.02	0.01	0.02	0.02
25	SD	0.2	0.9	1.0	0.6	0.3	2.1	0.01	0.01	0.01	0.01	0.01	0.01
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-45.1	-50.4	-43.6	-67.2	-71.9	-45.5	-56.25	-40.91	-13.33	-46.15	-21.43	-47.62
4	Mean	0.7	1.6	1.2	1.1	1.2	1.3	0.02	0.02	0.02	0.02	0.02	0.02
100	SD	0.5	0.9	0.9	1.1	1.4	1.0	0.01	0.02	0.01	0.01	0.01	0.01
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-15.7	-22.8	-33.6	-52.2	-37.7	-56.2	-37.50	-36.36	-6.67	-15.38	-28.57	-38.10

[a] - Anova & Dunnett  
[a1] - Anova & Dunnett(Log)  
[a2] - Kruskal-Wallis & Dunnett on Ranks

Table 5 Summary of Hematology-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Male		%BASO	%BASO	%BASO	%BASO	%BASO	%BASO	PLT	PLT	PLT	PLT	PLT	PLT
		(%)	(%)	(%)	(%)	(%)	(%)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)
		[a]	[a]	[a1]	[a1]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]
		-11	-6	53	87	123	179	-11	-6	53	87	123	179
1	Mean	0.3	0.3	0.3	0.3	0.3	0.4	402	410	363	338	330	338
0	SD	0.2	0.1	0.1	0.1	0.1	0.1	57	45	59	36	45	42
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	0.3	0.2	0.2	0.2	0.3	0.3	383	429	358	344	327	311
5	SD	0.1	0.1	0.0	0.0	0.1	0.1	76	74	57	62	52	66
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	0.0	-22.2	-20.0	-20.0	12.5	-14.3	-5	5	-1	2	-1	-8
3	Mean	0.1	0.2	0.2	0.2	0.2	0.2	411	449	371	355	345	359
25	SD	0.1	0.1	0.1	0.1	0.1	0.1	90	100	86	96	95	77
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-53.3	-27.8	-20.0	-33.3	-25.0	-38.1	2	10	2	5	5	6
4	Mean	0.2	0.2	0.2	0.2	0.2	0.3	396	453	386	352	342	332
100	SD	0.1	0.1	0.1	0.1	0.1	0.1	69	117	80	85	69	78
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-20.0	-38.9	-20.0	-20.0	-25.0	-9.5	-2	11	6	4	4	-2

[a] - Anova & Dunnett

[a1] - Kruskal-Wallis & Dunnett on Ranks

Table 5 Summary of Hematology-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Male		MPV	MPV	MPV	MPV	MPV	MPV
		(fL)	(fL)	(fL)	(fL)	(fL)	(fL)
		[a]	[a]	[a]	[a]	[a]	[a]
		-11	-6	53	87	123	179
1	Mean	8.0	8.0	8.6	8.9	9.5	9.4
0	SD	0.7	1.1	1.5	1.7	1.8	1.9
mg/kg/dose	N	6	6	6	6	6	6
2	Mean	7.8	7.6	8.3	8.3	9.1	9.2
5	SD	1.3	1.2	1.6	1.7	1.8	1.8
mg/kg/dose	N	6	6	6	6	6	6
	%Diff	-2.3	-4.4	-3.5	-6.0	-4.7	-2.5
3	Mean	7.8	7.5	8.1	8.4	9.3	9.2
25	SD	2.0	1.8	2.4	2.4	3.1	2.4
mg/kg/dose	N	6	6	6	6	6	6
	%Diff	-3.1	-5.7	-6.0	-5.8	-2.1	-2.3
4	Mean	7.6	7.6	8.1	8.2	8.9	8.8
100	SD	0.9	0.9	0.9	1.0	1.0	1.0
mg/kg/dose	N	6	6	6	6	6	6
	%Diff	-5.2	-4.4	-6.0	-8.1	-6.1	-6.0

[a] - Anova &amp; Dunnett

Table 5 Summary of Hematology-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Female		WBC	WBC	WBC	WBC	WBC	WBC	RBC	RBC	RBC	RBC	RBC	RBC
		(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>6</sup> /μL)	(x10 <sup>6</sup> /μL)	(x10 <sup>6</sup> /μL)	(x10 <sup>6</sup> /μL)	(x10 <sup>6</sup> /μL)	(x10 <sup>6</sup> /μL)
		[a]	[a1]	[a2]	[a]	[a1]	[a1]	[a1]	[a1]	[a1]	[a1]	[a1]	[a1]
		-12	-7	52	86	122	178	-12	-7	52	86	122	178
1	Mean	17.29	13.88	12.96	10.39	10.18	8.66	5.40	5.19	5.37	5.39	5.41	5.31
0	SD	5.12	4.78	2.54	1.97	2.31	2.69	0.17	0.21	0.18	0.37	0.23	0.24
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	16.42	12.45	11.13	11.00	7.33	8.37	5.88	5.61	5.87	5.82	5.11	5.61
5	SD	3.94	1.74	2.92	3.83	3.73	2.07	0.46	0.46	0.56	0.58	2.05	0.47
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-5.03	-10.31	-14.17	5.92	-27.99	-3.44	8.93	7.96	9.18	7.94	-5.55	5.78
3	Mean	11.73	10.97	7.44	7.51	7.72	7.17	5.57	5.45	5.60	5.38	5.64	5.34
25	SD	2.66	3.03	4.66	3.28	2.53	2.88	0.28	0.30	0.24	0.33	0.38	0.37
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-32.17	-20.97	-42.63	-27.65	-24.14	-17.22	3.15	4.88	4.25	-0.22	4.35	0.60
4	Mean	13.81	10.30	9.39	11.37	7.02	9.15	5.70	5.58	5.78	5.80	5.92	5.67
100	SD	5.94	4.09	5.30	6.41	3.17	5.00	0.70	0.68	0.31	0.47	0.54	0.60
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-20.11	-25.83	-27.56	9.52	-31.10	5.64	5.59	7.51	7.51	7.45	9.53	6.85

[a] - Anova & Dunnett(Log)  
[a1] - Anova & Dunnett  
[a2] - Kruskal-Wallis & Dunnett on Ranks

Table 5 Summary of Hematology-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Female		HGB	HGB	HGB	HGB	HGB	HGB	HCT	HCT	HCT	HCT	HCT	HCT
		(g/dL)	(g/dL)	(g/dL)	(g/dL)	(g/dL)	(g/dL)	(%)	(%)	(%)	(%)	(%)	(%)
		[a]	[a1]	[a2]	[a1]	[a2]	[a1]	[a1]	[a2]	[a2]	[a1]	[a2]	[a1]
		-12	-7	52	86	122	178	-12	-7	52	86	122	178
1	Mean	12.8	12.3	12.8	12.7	13.1	12.7	42.1	40.4	41.7	41.4	41.5	41.6
0	SD	0.9	0.8	0.6	0.9	0.6	0.7	2.4	2.1	1.6	3.2	1.8	2.7
	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	13.7	13.0	13.5	13.2	12.0	13.0	44.2	42.5	43.7	43.0	37.7	41.9
5	SD	1.2	1.1	1.4	1.2	4.9	1.1	3.7	3.1	3.8	3.1	14.9	2.8
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	7.2	5.7	5.3	4.5	-8.7	2.4	5.1	5.2	4.8	3.7	-9.2	0.8
3	Mean	13.0	12.9	13.3	12.5	13.4	12.8	43.3	42.9	43.6	41.4	43.5	41.7
25	SD	0.5	0.4	0.4	0.8	0.6	0.8	2.0	1.2	1.3	2.8	2.3	2.7
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	1.8	5.2	3.5	-1.6	2.4	0.7	3.0	6.2	4.5	0.0	4.7	0.2
4	Mean	13.1	12.9	13.4	13.3	13.9	13.3	44.1	43.4	43.9	43.7	44.9	43.7
100	SD	0.8	0.8	0.5	0.4	0.7	0.5	3.3	2.4	1.7	1.9	2.6	3.5
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	3.0	5.2	4.7	4.9	6.0	4.2	4.9	7.4	5.2	5.5	8.2	5.0

[a] - Anova & Dunnett(Log)  
 [a1] - Anova & Dunnett  
 [a2] - Kruskal-Wallis & Dunnett on Ranks

Table 5 Summary of Hematology-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Female		MCV	MCV	MCV	MCV	MCV	MCV	MCH	MCH	MCH	MCH	MCH	MCH
		(fL)	(fL)	(fL)	(fL)	(fL)	(fL)	(pg)	(pg)	(pg)	(pg)	(pg)	(pg)
		[a]	[a]	[a]	[a]	[a]	[a1]	[a]	[a]	[a]	[a]	[a]	[a]
		-12	-7	52	86	122	178	-12	-7	52	86	122	178
1	Mean	77.8	77.7	77.7	76.8	76.8	78.4	23.6	23.6	23.9	23.5	24.2	24.0
0	SD	2.9	1.2	2.7	2.3	2.5	2.0	0.9	0.8	0.7	0.8	0.7	0.7
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	75.3	75.9	74.7	74.0	73.9	74.8	23.3	23.2	23.1	22.8	23.2	23.3
5	SD	5.0	4.7	4.6	3.9	4.1	5.4	1.6	1.5	1.5	1.5	2.0	1.8
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-3.2	-2.3	-3.9	-3.6	-3.8	-4.5	-1.4	-1.6	-3.4	-3.2	-4.4	-2.8
3	Mean	77.9	78.8	77.9	77.0	77.1	78.1	23.4	23.8	23.7	23.2	23.8	24.0
25	SD	3.0	2.8	2.2	2.8	1.7	2.3	0.9	0.9	0.6	1.0	0.7	0.8
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	0.1	1.4	0.3	0.2	0.3	-0.3	-0.8	0.8	-0.9	-1.3	-1.7	0.1
4	Mean	77.9	78.3	76.2	75.7	76.2	77.3	23.2	23.3	23.2	23.0	23.6	23.6
100	SD	5.9	6.6	5.5	5.7	7.1	6.0	1.7	1.8	1.6	1.8	1.9	2.0
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	0.1	0.8	-1.9	-1.4	-0.7	-1.3	-1.7	-1.1	-2.7	-2.1	-2.6	-1.7

[a] - Anova & Dunnett

[a1] - Kruskal-Wallis & Dunnett on Ranks



Table 5 Summary of Hematology-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Female		MCHC	MCHC	MCHC	MCHC	MCHC	MCHC	RDW	RDW	RDW	RDW	RDW	RDW
		(g/dL)	(g/dL)	(g/dL)	(g/dL)	(g/dL)	(g/dL)	(%)	(%)	(%)	(%)	(%)	(%)
		[a]	[a]	[a]	[a1]	[a]	[a]	[a]	[a]	[a]	[a]	[a1]	[a]
		-12	-7	52	86	122	178	-12	-7	52	86	122	178
1	Mean	30.3	30.3	30.7	30.6	31.6	30.6	13.3	13.4	13.0	12.9	12.6	13.3
0	SD	1.0	0.7	1.1	0.6	1.1	0.9	0.7	0.7	0.6	0.6	0.6	0.6
	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	30.9	30.6	30.9	30.7	31.3	31.1	13.0	13.0	12.8	12.8	13.7	13.3
5	SD	0.4	0.4	0.7	1.0	1.4	0.9	0.3	0.2	0.3	0.3	3.5	0.6
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	1.9	0.8	0.5	0.4	-0.7	1.6	-1.9	-3.0	-1.4	-0.9	9.0	-0.4
3	Mean	30.0	30.2	30.4	30.2	30.9	30.8	13.1	13.1	12.8	12.9	12.4	13.1
25	SD	0.8	0.8	0.8	1.2	0.9	0.8	0.5	0.4	0.6	0.4	0.4	0.6
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-0.9	-0.5	-1.0	-1.3	-2.0	0.4	-1.5	-2.2	-1.4	-0.5	-1.2	-2.0
4	Mean	29.8	29.8	30.5	30.4	31.0	30.5	13.8	13.7	13.0	13.1	12.6	13.5
100	SD	0.6	0.6	0.4	0.6	0.7	1.1	0.6	0.5	0.5	0.8	0.6	0.6
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-1.7	-1.9	-0.8	-0.7	-1.9	-0.3	3.8	2.4	0.1	1.4	0.0	1.0

[a] - Anova & Dunnett

[a1] - Kruskal-Wallis & Dunnett on Ranks

Table 5 Summary of Hematology-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Female		#RET	#RET	#RET	#RET	#RET	#RET	#NEUT	#NEUT	#NEUT	#NEUT	#NEUT	#NEUT
		(x10 <sup>9</sup> /L)	(x10 <sup>9</sup> /L)	(x10 <sup>9</sup> /L)	(x10 <sup>9</sup> /L)	(x10 <sup>9</sup> /L)	(x10 <sup>9</sup> /L)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)
		[a]	[a]	[a]	[a]	[a]	[a1]	[a2]	[a]	[a]	[a]	[a]	[a]
		-12	-7	52	86	122	178	-12	-7	52	86	122	178
1	Mean	52.9	69.1	47.0	56.0	69.8	55.9	12.19	8.74	7.70	6.41	5.37	4.11
0	SD	6.2	18.5	12.1	17.7	16.7	8.4	4.74	4.48	2.66	1.88	2.78	3.03
	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	57.2	81.6	67.3	63.3	77.6	70.1	11.44	7.07	6.33	7.03	3.34	3.66
5	SD	19.9	31.6	14.9	16.6	16.8	14.7	4.41	2.12	2.91	4.13	3.62	1.25
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	8.2	18.0	43.2	13.0	11.1	25.4	-6.22	-19.14	-17.77	9.65	-37.85	-10.98
3	Mean	45.6	66.5	49.3	53.9	64.3	61.6	7.04	5.79	2.92	3.71	3.01	2.24
25	SD	8.4	20.7	16.0	16.9	12.2	17.9	2.04	2.50	2.52	2.27	1.51	1.03
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-13.8	-3.8	4.8	-3.7	-7.9	10.1	-42.26	-33.78	-62.07	-42.10	-43.93	-45.54
4	Mean	75.9	92.2	57.6	59.4	67.5	64.9	9.59	5.21	4.57	7.18	2.82	4.71
100	SD	38.4	43.7	21.0	23.3	21.6	26.5	5.27	2.37	3.61	4.49	2.23	2.88
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	43.6	33.4	22.5	6.1	-3.3	16.1	-21.36	-40.43	-40.68	11.96	-47.53	14.47

[a] - Anova &amp; Dunnett

[a1] - Anova &amp; Dunnett(Log)

[a2] - Kruskal-Wallis &amp; Dunnett on Ranks

Table 5 Summary of Hematology-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Female		%NEUT	%NEUT	%NEUT	%NEUT	%NEUT	%NEUT	#LYMP	#LYMP	#LYMP	#LYMP	#LYMP	#LYMP
		(%)	(%)	(%)	(%)	(%)	(%)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)
		[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]
		-12	-7	52	86	122	178	-12	-7	52	86	122	178
1	Mean	69.0	60.2	58.3	61.0	50.0	44.4	4.55	4.49	4.68	3.55	4.31	4.05
0	SD	8.6	13.5	10.3	8.5	17.1	18.4	1.02	1.08	1.09	0.62	0.84	1.07
	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	67.9	56.2	55.1	61.2	38.9	44.1	4.32	4.70	4.30	3.56	3.65	4.34
5	SD	12.3	12.7	12.1	12.5	19.5	10.2	1.45	1.22	0.90	0.91	1.16	1.39
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-1.6	-6.7	-5.5	0.2	-22.3	-0.8	-5.02	4.75	-8.08	0.23	-15.33	6.99
3	Mean	59.5	51.0	35.3*	47.3	38.2	31.4	4.17	4.71	4.07	3.42	4.31	4.52
25	SD	8.1	11.8	13.9	15.5	13.5	9.6	1.16	1.15	2.48	1.51	1.82	1.93
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-13.8	-15.3	-39.4	-22.4	-23.7	-29.4	-8.32	4.79	-13.07	-3.66	0.08	11.56
4	Mean	67.8	50.7	42.9	60.9	37.0	49.4	3.76	4.58	4.30	3.76	3.87	4.04
100	SD	14.7	10.7	15.1	12.6	14.3	12.8	1.86	2.10	1.73	1.87	1.72	2.14
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-1.8	-15.8	-26.5	-0.2	-26.0	11.1	-17.41	2.08	-8.19	5.82	-10.10	-0.29

[a] - Anova &amp; Dunnett: \* = p ≤ 0.05

Table 5 Summary of Hematology-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Female		%LYMP	%LYMP	%LYMP	%LYMP	%LYMP	%LYMP	#MONO	#MONO	#MONO	#MONO	#MONO	#MONO
		(%)	(%)	(%)	(%)	(%)	(%)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)
		[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]
		-12	-7	52	86	122	178	-12	-7	52	86	122	178
1	Mean	27.8	35.1	37.1	35.0	45.2	49.6	0.27	0.30	0.37	0.28	0.33	0.31
0	SD	8.4	13.3	9.4	7.7	17.0	16.6	0.10	0.17	0.19	0.13	0.26	0.18
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	27.7	38.3	40.1	34.9	56.0	51.4	0.33	0.25	0.33	0.29	0.22	0.26
5	SD	10.6	10.8	10.8	12.0	19.1	9.8	0.11	0.07	0.11	0.07	0.08	0.08
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-0.5	9.0	8.3	-0.2	23.9	3.5	23.60	-15.73	-10.45	2.99	-35.50	-18.09
3	Mean	35.7	44.1	58.0*	47.3	56.4	62.7	0.27	0.26	0.29	0.26	0.27	0.30
25	SD	6.2	9.1	13.1	14.7	13.2	8.5	0.10	0.11	0.15	0.12	0.07	0.15
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	28.4	25.6	56.5	35.3	25.0	26.4	0.62	-13.48	-21.82	-7.19	-20.00	-5.85
4	Mean	28.8	44.3	51.1	35.1	57.7	45.7	0.24	0.23	0.23	0.25	0.19	0.27
100	SD	13.7	10.2	13.8	11.4	13.0	11.9	0.11	0.07	0.07	0.13	0.06	0.11
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	3.6	26.1	37.8	0.3	27.8	-7.9	-9.94	-23.60	-37.73	-10.18	-42.50	-14.36

[a] - Anova & Dunnett: \* = p ≤ 0.05

Table 5 Summary of Hematology-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Female		%MONO	%MONO	%MONO	%MONO	%MONO	%MONO	#EOS	#EOS	#EOS	#EOS	#EOS	#EOS
		(%)	(%)	(%)	(%)	(%)	(%)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)
		[a]	[a1]	[a]	[a]	[a]	[a]	[a]	[a]	[a1]	[a1]	[a]	[a]
		-12	-7	52	86	122	178	-12	-7	52	86	122	178
1	Mean	1.6	2.1	2.9	2.6	3.1	3.6	0.18	0.27	0.13	0.08	0.10	0.13
0	SD	0.4	0.6	1.4	1.0	1.7	1.9	0.12	0.33	0.05	0.04	0.04	0.13
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	2.1	2.0	3.2	2.7	3.2	3.2	0.23	0.33	0.08	0.06	0.07	0.05
5	SD	0.9	0.6	1.3	0.9	0.9	1.0	0.18	0.32	0.07	0.03	0.08	0.04
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	36.6	-2.4	9.2	3.2	2.7	-11.5	27.78	22.64	-38.46	-19.15	-30.51	-58.97
3	Mean	2.5	2.7	4.2	3.6	3.6	4.2	0.14	0.14	0.09	0.05	0.07	0.05
25	SD	1.3	1.9	1.3	1.4	1.1	1.7	0.13	0.07	0.06	0.04	0.02	0.03
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	58.1	29.0	46.2	38.0	16.8	15.2	-22.22	-49.06	-33.33	-40.43	-33.90	-58.97
4	Mean	1.8	2.3	3.0	2.3	3.2	3.2	0.14	0.18	0.21	0.12	0.06	0.07
100	SD	0.5	0.5	1.7	0.7	1.4	1.2	0.11	0.18	0.28	0.12	0.06	0.06
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	15.1	12.1	4.6	-12.7	2.2	-11.1	-20.37	-32.70	60.26	46.81	-40.68	-47.44

[a] - Anova &amp; Dunnett

[a1] - Anova &amp; Dunnett(Log)

Table 5 Summary of Hematology-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Female		%EOS	%EOS	%EOS	%EOS	%EOS	%EOS	#BASO	#BASO	#BASO	#BASO	#BASO	#BASO
		(%)	(%)	(%)	(%)	(%)	(%)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)
		[a]	[a]	[a]	[a1]	[a2]	[a]	[a]	[a]	[a]	[a2]	[a]	[a]
		-12	-7	52	86	122	178	-12	-7	52	86	122	178
1	Mean	1.0	1.9	1.1	0.8	1.0	1.7	0.03	0.02	0.02	0.02	0.02	0.02
0	SD	0.5	2.1	0.5	0.3	0.5	1.8	0.01	0.01	0.01	0.01	0.01	0.01
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	1.6	2.7	0.8	0.6	1.0	0.6	0.03	0.02	0.02	0.02	0.02	0.02
5	SD	1.4	2.7	0.8	0.3	1.2	0.5	0.02	0.01	0.01	0.01	0.01	0.02
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	56.5	40.5	-25.0	-17.8	-8.1	-64.7	13.33	18.18	7.69	11.11	-10.00	40.00
3	Mean	1.3	1.4	1.4	0.6	0.8	0.7	0.02	0.02	0.02	0.01	0.02	0.02
25	SD	1.4	1.0	1.2	0.4	0.3	0.2	0.01	0.01	0.02	0.01	0.01	0.01
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	29.0	-27.6	32.8	-24.4	-21.0	-56.9	-13.33	9.09	-7.69	-11.11	10.00	10.00
4	Mean	1.0	1.6	1.9	1.2	0.9	1.0	0.02	0.02	0.02	0.02	0.02	0.02
100	SD	0.7	1.5	1.9	1.4	0.9	1.2	0.01	0.01	0.01	0.02	0.01	0.02
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-8.1	-16.4	78.1	60.0	-12.9	-43.1	-26.67	0.00	-15.38	22.22	0.00	20.00

[a] - Anova & Dunnett  
[a1] - Anova & Dunnett(Log)  
[a2] - Kruskal-Wallis & Dunnett on Ranks

Table 5 Summary of Hematology-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Female		%BASO	%BASO	%BASO	%BASO	%BASO	%BASO	PLT	PLT	PLT	PLT	PLT	PLT
		(%)	(%)	(%)	(%)	(%)	(%)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)	(x10 <sup>3</sup> /μL)
		[a]	[a]	[a]	[a]	[a]	[a]	[a1]	[a]	[a]	[a]	[a]	[a]
		-12	-7	52	86	122	178	-12	-7	52	86	122	178
1	Mean	0.2	0.2	0.2	0.2	0.2	0.2	558	539	459	420	419	428
0	SD	0.1	0.1	0.1	0.1	0.1	0.1	71	118	89	78	91	59
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	0.2	0.2	0.2	0.2	0.2	0.3	421 *	433	362	324	308	345
5	SD	0.1	0.0	0.1	0.1	0.1	0.2	141	97	92	67	124	73
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	22.2	22.2	33.3	-10.0	0.0	14.3	-25	-20	-21	-23	-26	-20
3	Mean	0.2	0.2	0.3	0.2	0.3	0.2	423 *	485	388	358	397	352
25	SD	0.0	0.1	0.1	0.1	0.1	0.1	60	109	57	39	53	52
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	22.2	22.2	66.7	0.0	25.0	0.0	-24	-10	-16	-15	-5	-18
4	Mean	0.2	0.2	0.2	0.2	0.2	0.2	422 *	437	372	355	373	365
100	SD	0.1	0.1	0.0	0.1	0.1	0.1	96	81	58	85	72	70
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	11.1	0.0	44.4	-10.0	8.3	-14.3	-24	-19	-19	-16	-11	-15

[a] - Anova &amp; Dunnett

[a1] - Kruskal-Wallis &amp; Dunnett on Ranks: \* = p ≤ 0.05

Table 5 Summary of Hematology-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Female		MPV	MPV	MPV	MPV	MPV	MPV
		(fL)	(fL)	(fL)	(fL)	(fL)	(fL)
		[a]	[a]	[a]	[a]	[a]	[a]
		-12	-7	52	86	122	178
1	Mean	7.1	7.1	7.8	7.8	8.7	8.5
0	SD	0.7	0.8	1.1	1.0	1.6	1.0
mg/kg/dose	N	6	6	6	6	6	6
2	Mean	7.8	7.4	8.5	8.3	9.1	9.4
5	SD	0.8	0.7	1.0	0.9	0.6	1.0
mg/kg/dose	N	6	6	6	6	6	6
	%Diff	9.1	4.2	8.3	7.1	4.2	10.4
3	Mean	7.7	7.6	8.8	8.6	9.2	9.6
25	SD	0.6	0.5	1.2	0.7	0.9	0.7
mg/kg/dose	N	6	6	6	6	6	6
	%Diff	8.2	6.8	12.8	10.3	5.5	12.1
4	Mean	8.0	7.8	8.4	8.7	9.5	9.7
100	SD	0.8	0.7	0.8	0.9	1.3	0.9
mg/kg/dose	N	6	6	6	6	6	6
	%Diff	11.7	9.9	7.7	11.1	9.2	13.3

[a] - Anova &amp; Dunnett



Table 5 Summary of Hematology-Recovery Phase

Day: 209 Relative to Start Date

Sex: Female		WBC	RBC	HGB	HCT	MCV	MCH	MCHC	RDW	#RET	#NEUT	%NEUT	#LYMP
		(x10 <sup>3</sup> /μL)	(x10 <sup>6</sup> /μL)	(g/dL)	(%)	(fL)	(pg)	(g/dL)	(%)	(x10 <sup>9</sup> /L)	(x10 <sup>3</sup> /μL)	(%)	(x10 <sup>3</sup> /μL)
1 0 mg/kg/dose	Mean	9.77	5.25	12.9	43.0	82.0	24.7	30.1	13.5	68.6	4.69	49.5	4.68
	SD	1.29	0.04	0.4	0.1	1.1	1.1	0.9	0.7	3.4	1.50	21.8	2.64
	N	2	2	2	2	2	2	2	2	2	2	2	2
2 5 mg/kg/dose	Mean	10.63	6.20	14.2	44.8	72.2	22.8	31.6	14.0	65.9	4.44	41.9	5.64
	SD	3.19	0.49	1.6	4.2	1.0	0.8	0.6	0.6	10.2	1.24	0.8	1.68
	N	2	2	2	2	2	2	2	2	2	2	2	2
	%Diff	8.75	18.00	9.7	4.1	-11.9	-7.5	5.0	3.3	-3.9	-5.33	-15.3	20.64
3 25 mg/kg/dose	Mean	5.35	5.48	13.3	43.9	80.3	24.3	30.3	12.7	72.2	2.08	39.0	2.84
	SD	0.25	0.47	1.3	3.1	1.3	0.1	0.6	0.1	7.1	0.16	4.9	0.29
	N	2	2	2	2	2	2	2	2	2	2	2	2
	%Diff	-45.29	4.29	3.1	2.1	-2.0	-1.4	0.7	-6.3	5.2	-55.76	-21.2	-39.36
4 100 mg/kg/dose	Mean	6.25	5.63	13.3	44.1	78.3	23.7	30.2	13.3	60.7	3.13	49.6	2.90
	SD	1.96	0.21	0.7	3.2	2.8	0.2	0.7	0.3	16.1	1.14	2.7	0.88
	N	2	2	2	2	2	2	2	2	2	2	2	2
	%Diff	-36.08	7.14	3.1	2.4	-4.5	-4.1	0.5	-1.5	-11.6	-33.37	0.3	-37.97

Table 5 Summary of Hematology-Recovery Phase (Cont'd)

Day: 209 Relative to Start Date

Sex: Female		%LYMP	#MONO	%MONO	#EOS	%EOS	#BASO	%BASO	PLT	MPV
		(%)	(x10 <sup>3</sup> /μL)	(%)	(x10 <sup>3</sup> /μL)	(%)	(x10 <sup>3</sup> /μL)	(%)	(x10 <sup>3</sup> /μL)	(fL)
1	Mean	46.5	0.25	2.6	0.11	1.0	0.03	0.2	387	8.4
0	SD	20.9	0.04	0.1	0.08	0.7	0.01	0.0	87	0.4
mg/kg/dose	N	2	2	2	2	2	2	2	2	2
2	Mean	53.1	0.42	3.9	0.07	0.6	0.04	0.4	352	9.0
5	SD	0.1	0.16	0.4	0.06	0.4	0.03	0.1	126	0.4
mg/kg/dose	N	2	2	2	2	2	2	2	2	2
	%Diff	14.2	66.00	51.0	-38.10	-40.0	60.00	100.0	-9	6.5
3	Mean	53.0	0.35	6.4	0.05	0.9	0.02	0.3	359	8.4
25	SD	3.1	0.15	2.4	0.03	0.6	0.01	0.1	52	0.4
mg/kg/dose	N	2	2	2	2	2	2	2	2	2
	%Diff	14.0	38.00	151.0	-52.38	-10.0	-40.00	25.0	-7	0.0
4	Mean	46.5	0.15	2.7	0.03	0.5	0.01	0.2	318	9.5
100	SD	0.5	0.01	1.1	0.02	0.6	0.00	0.1	1	0.2
mg/kg/dose	N	2	2	2	2	2	2	2	2	2
	%Diff	-0.1	-40.00	3.9	-76.19	-50.0	-60.00	-25.0	-18	12.5

Table 5 Summary of Hematology-Recovery Phase (Cont'd)

Day: 210 Relative to Start Date

Sex: Male		WBC	RBC	HGB	HCT	MCV	MCH	MCHC	RDW	#RET	#NEUT	%NEUT	#LYMP
		(x10 <sup>3</sup> /μL)	(x10 <sup>6</sup> /μL)	(g/dL)	(%)	(fL)	(pg)	(g/dL)	(%)	(x10 <sup>9</sup> /L)	(x10 <sup>3</sup> /μL)	(%)	(x10 <sup>3</sup> /μL)
1 0 mg/kg/dose	Mean	11.16	5.88	13.6	45.8	78.0	23.1	29.6	14.4	74.2	3.94	35.0	6.22
	SD	1.02	0.11	0.4	2.3	2.5	0.1	0.8	0.3	22.1	1.07	6.4	0.45
	N	2	2	2	2	2	2	2	2	2	2	2	2
2 5 mg/kg/dose	Mean	10.94	5.62	12.9	42.2	75.0	22.9	30.5	13.8	84.4	2.60	23.9	7.72
	SD	0.74	0.07	0.4	0.8	2.4	1.0	0.3	0.5	13.5	0.42	5.5	1.32
	N	2	2	2	2	2	2	2	2	2	2	2	2
	%Diff	-2.02	-4.34	-5.2	-8.0	-3.8	-0.7	3.0	-4.5	13.7	-34.14	-31.6	24.14
3 25 mg/kg/dose	Mean	7.96	5.60	14.0	45.2	80.7	25.0	30.9	14.3	61.5	2.37	30.3	5.26
	SD	0.46	0.01	0.3	1.1	1.8	0.5	0.1	0.4	7.9	1.26	17.5	1.55
	N	2	2	2	2	2	2	2	2	2	2	2	2
	%Diff	-28.72	-4.68	3.3	-1.4	3.5	8.2	4.4	-0.7	-17.1	-39.85	-13.3	-15.45
4 100 mg/kg/dose	Mean	9.45	5.90	14.0	45.2	76.9	23.7	30.9	13.9	51.6	3.68	39.1	5.44
	SD	0.09	0.98	1.6	5.6	3.5	1.3	0.3	0.3	5.1	2.36	25.5	2.46
	N	2	2	2	2	2	2	2	2	2	2	2	2
	%Diff	-15.37	0.34	3.0	-1.4	-1.4	2.8	4.4	-3.5	-30.5	-6.60	11.9	-12.47

Table 5 Summary of Hematology-Recovery Phase (Cont'd)

Day: 210 Relative to Start Date

Sex: Male		%LYMP	#MONO	%MONO	#EOS	%EOS	#BASO	%BASO	PLT	MPV
		(%)	(x10 <sup>3</sup> /μL)	(%)	(x10 <sup>3</sup> /μL)	(%)	(x10 <sup>3</sup> /μL)	(%)	(x10 <sup>3</sup> /μL)	(fL)
1	Mean	55.8	0.37	3.3	0.55	5.2	0.03	0.3	356	8.4
0	SD	1.1	0.08	0.4	0.61	5.9	0.00	0.0	35	0.4
mg/kg/dose	N	2	2	2	2	2	2	2	2	2
2	Mean	70.4	0.41	3.8	0.14	1.3	0.04	0.3	338	8.8
5	SD	7.3	0.11	1.2	0.08	0.8	0.01	0.0	78	2.8
mg/kg/dose	N	2	2	2	2	2	2	2	2	2
	%Diff	26.2	9.46	13.6	-75.45	-75.7	16.67	0.0	-5	4.8
3	Mean	65.6	0.27	3.3	0.04	0.4	0.02	0.2	273	12.1
25	SD	15.7	0.15	1.7	0.01	0.1	0.01	0.0	78	3.7
mg/kg/dose	N	2	2	2	2	2	2	2	2	2
	%Diff	17.7	-28.38	0.0	-93.64	-93.2	-50.00	-33.3	-23	44.0
4	Mean	57.5	0.18	1.9	0.08	0.8	0.03	0.3	305	8.6
100	SD	25.5	0.01	0.1	0.03	0.3	0.00	0.0	40	1.5
mg/kg/dose	N	2	2	2	2	2	2	2	2	2
	%Diff	3.1	-51.35	-42.4	-85.45	-84.5	0.00	0.0	-14	1.8

**Table 6      Summary of Coagulation**

Table 6 Summary of Coagulation

Key Page

**Measurement Descriptions**

Headings Used

PT  
APTT  
FIB

Description

Prothrombin Time  
Activated Partial Thromboplastin Time  
Fibrinogen

Table 6 Summary of Coagulation-Pretest and Dosing Phase

Day(s) Relative to Start Date

Sex: Male		PT	PT	PT	PT	PT	PT	APTT	APTT	APTT	APTT	APTT	APTT
		(Sec)	(Sec)	(Sec)	(Sec)	(Sec)	(Sec)	(Sec)	(Sec)	(Sec)	(Sec)	(Sec)	(Sec)
		[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a1]	[a]	[a]	[a]	[a]
		-11	-6	53	87	123	179	-11	-6	53	87	123	179
1	Mean	11.2	10.0	12.7	11.9	13.9	14.1	17.5	17.7	17.5	17.6	17.8	18.0
0	SD	0.4	0.8	2.9	1.2	2.0	1.9	0.6	1.0	0.9	1.3	1.4	1.4
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	11.0	10.4	11.1	11.1	13.0	11.7*	17.9	18.0	18.3	18.3	18.9	18.7
5	SD	1.0	0.9	0.9	0.6	1.3	1.1	1.0	0.9	0.6	0.9	1.0	1.2
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-2.2	4.2	-12.0	-6.9	-6.8	-16.8	1.8	2.1	4.5	3.9	6.1	3.7
3	Mean	11.6	10.3	12.0	13.5	14.0	12.7	18.2	18.4	18.0	18.3	19.6	18.2
25	SD	1.3	0.6	1.7	3.5	1.7	1.1	1.3	1.4	1.1	1.3	2.3	1.6
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	3.0	2.7	-5.1	13.7	0.5	-9.6	3.9	4.2	3.0	4.0	10.3	1.1
4	Mean	11.2	10.3	11.7	11.7	15.1	12.2	17.4	17.4	17.2	17.5	18.0	17.4
100	SD	0.4	0.5	1.6	1.2	3.0	1.3	1.6	2.2	1.7	1.6	1.6	1.7
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	0.1	3.3	-7.9	-1.3	8.5	-13.6	-1.0	-1.2	-1.6	-0.3	1.4	-3.2

[a] - Anova & Dunnett: \* =  $p \leq 0.05$ 

[a1] - Kruskal-Wallis &amp; Dunnett on Ranks

Table 6 Summary of Coagulation-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Male		FIB	FIB	FIB	FIB	FIB	FIB
		(g/L)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)
		[a]	[a]	[a]	[a1]	[a1]	[a2]
		-11	-6	53	87	123	179
1	Mean	2.20	2.64	2.35	2.30	1.97	2.64
0	SD	0.45	0.49	0.59	0.52	0.45	0.64
mg/kg/dose	N	6	6	6	6	6	6
2	Mean	2.32	2.53	2.24	2.35	1.94	2.30
5	SD	0.55	0.50	0.30	0.60	0.39	0.38
mg/kg/dose	N	6	6	6	6	6	6
	%Diff	5.47	-4.05	-4.47	2.03	-1.78	-12.82
3	Mean	2.53	3.08	2.51	2.47	3.18	2.66
25	SD	0.18	0.62	0.35	0.31	2.47	0.15
mg/kg/dose	N	6	6	6	6	6	6
	%Diff	15.34	16.95	6.82	7.02	61.25	0.88
4	Mean	2.61	2.63	2.45	2.40	1.90	2.24
100	SD	0.62	0.30	0.51	0.92	0.53	0.34
mg/kg/dose	N	6	6	6	6	6	6
	%Diff	18.68	-0.32	4.40	4.20	-3.72	-15.28

[a] - Anova &amp; Dunnett

[a1] - Anova &amp; Dunnett(Log)

[a2] - Kruskal-Wallis &amp; Dunnett on Ranks



Table 6 Summary of Coagulation-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Female		PT	PT	PT	PT	PT	PT	APTT	APTT	APTT	APTT	APTT	APTT
		(Sec)	(Sec)	(Sec)	(Sec)	(Sec)	(Sec)	(Sec)	(Sec)	(Sec)	(Sec)	(Sec)	(Sec)
		[a]	[a1]	[a]	[a1]	[a1]	[a1]	[a1]	[a1]	[a1]	[a1]	[a1]	[a1]
		-12	-7	52	86	122	178	-12	-7	52	86	122	178
1	Mean	11.0	10.0	10.3	11.9	13.2	12.5	18.2	17.9	17.8	18.2	18.3	17.9
0	SD	0.8	0.3	0.6	1.5	1.0	1.6	1.3	1.3	1.0	1.5	1.1	0.9
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	11.2	10.1	10.3	11.7	12.5	11.0	18.9	18.5	18.0	18.7	19.0	18.7
5	SD	1.4	0.9	1.5	1.1	2.2	1.1	2.0	2.1	2.1	1.8	1.9	2.2
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	2.1	0.8	0.3	-2.4	-4.8	-12.2	4.2	3.4	1.1	2.7	3.5	4.4
3	Mean	11.2	10.0	10.7	12.2	14.0	12.7	17.7	16.8	16.7	17.3	17.7	17.1
25	SD	1.2	0.7	0.4	1.3	1.4	2.5	1.1	1.3	1.2	1.5	1.2	1.3
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	2.3	0.2	3.6	1.8	6.1	2.1	-2.8	-6.4	-6.2	-5.2	-3.5	-4.4
4	Mean	12.6	10.4	10.9	12.3	16.2	14.4	18.0	17.7	17.4	18.1	18.7	17.5
100	SD	2.3	1.0	0.6	0.8	5.7	3.1	1.7	1.9	1.8	2.0	1.9	2.0
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	14.4	4.0	5.5	2.9	22.7	15.2	-1.1	-1.4	-2.4	-0.5	1.9	-2.4

[a] - Kruskal-Wallis & Dunnett on Ranks

[a1] - Anova & Dunnett

Table 6 Summary of Coagulation-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Female		FIB	FIB	FIB	FIB	FIB	FIB
		(g/L)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)
		[a]	[a]	[a]	[a]	[a]	[a]
		-12	-7	52	86	122	178
1	Mean	2.35	2.38	2.59	2.28	2.03	2.28
0	SD	0.31	0.46	0.56	0.48	0.43	0.50
mg/kg/dose	N	6	6	6	6	6	6
2	Mean	2.41	2.35	2.46	2.31	2.10	2.25
5	SD	0.58	0.46	0.30	0.60	0.57	0.46
mg/kg/dose	N	6	6	6	6	6	6
	%Diff	2.63	-1.26	-4.96	1.39	3.70	-1.39
3	Mean	2.39	2.12	2.25	1.93	1.87	2.14
25	SD	0.97	0.34	0.55	0.59	0.49	0.43
mg/kg/dose	N	6	6	6	6	6	6
	%Diff	1.85	-10.93	-13.07	-15.37	-7.90	-6.22
4	Mean	2.10	2.33	2.18	1.97	1.90	2.14
100	SD	0.54	0.55	0.31	0.24	0.26	0.42
mg/kg/dose	N	6	6	6	6	6	6
	%Diff	-10.37	-2.24	-15.65	-13.40	-6.01	-5.93

[a] - Anova &amp; Dunnett

Table 6 Summary of Coagulation-Recovery Phase

Day: 209 Relative to Start Date

Sex: Female		PT	APTT	FIB
		(Sec)	(Sec)	(g/L)
1	Mean	16.9	17.0	2.21
0	SD	0.6	0.1	0.21
mg/kg/dose	N	2	2	2
2	Mean	13.9	19.0	1.84
5	SD	0.8	0.9	0.32
mg/kg/dose	N	2	2	2
	%Diff	-17.8	11.5	-16.78
3	Mean	18.0	18.2	2.10
25	SD	1.0	1.3	0.91
mg/kg/dose	N	2	2	2
	%Diff	6.5	6.8	-4.99
4	Mean	14.0	20.1	2.39
100	SD	0.6	1.3	0.24
mg/kg/dose	N	2	2	2
	%Diff	-17.5	17.9	8.39

Table 6 Summary of Coagulation-Recovery Phase (Cont'd)

Day: 210 Relative to Start Date

Sex: Male		PT	APTT	FIB
		(Sec)	(Sec)	(g/L)
1	Mean	19.4	18.3	2.53
0	SD	1.3	0.1	0.18
mg/kg/dose	N	2	2	2
2	Mean	14.3	19.6	2.84
5	SD	1.3	0.1	0.30
mg/kg/dose	N	2	2	2
	%Diff	-26.4	7.1	12.28
3	Mean	18.1	18.1	2.68
25	SD	1.6	1.0	0.32
mg/kg/dose	N	2	2	2
	%Diff	-6.5	-0.8	5.94
4	Mean	12.4	18.3	2.58
100	SD	0.8	3.3	0.62
mg/kg/dose	N	2	2	2
	%Diff	-35.9	0.0	2.18

**Table 7      Summary of Chemistry**

Table 7 Summary of Chemistry

Key Page**Measurement Descriptions**Headings Used

ALT

AST

TP

ALB

TBIL

ALP

GGT

sGLU

UREA

CRE

Ca

P

TCHO

TG

K

Na

Cl

GLB

A/G

CK

Description

Alanine Aminotransferase

Aspartate Aminotransferase

Total Protein

Albumin

Total Bilirubin

Alkaline Phosphatase

Gamma-Glutamytransferase

Glucose

Urea

Creatinine

Calcium

Inorganic Phosphorus

Total Cholesterol

Triglyceride

Potassium

Sodium

Chloride

Globulin

A/G Ratio

Creatine Kinase

Table 7 Summary of Chemistry-Pretest and Dosing Phase

Day(s) Relative to Start Date

Sex: Male		ALT	ALT	ALT	ALT	ALT	ALT	AST	AST	AST	AST	AST	AST
		(U/L)	(U/L)	(U/L)	(U/L)	(U/L)	(U/L)	(U/L)	(U/L)	(U/L)	(U/L)	(U/L)	(U/L)
		[a]	[a]	[a1]	[a]	[a]	[a]	[a]	[a1]	[a]	[a]	[a]	[a]
		-11	-6	53	87	123	179	-11	-6	53	87	123	179
1	Mean	50	58	44	57	39	43	60	70	51	70	45	56
0	SD	9	13	7	16	6	9	14	24	10	33	6	11
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	53	56	53	70	47	53	62	70	55	74	51	58
5	SD	19	17	21	26	12	13	15	15	15	30	18	21
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	5	-4	21	24	21	22	3	1	7	6	12	3
3	Mean	51	48	47	58	42	46	49	50	42	62	44	46
25	SD	7	6	10	13	6	11	12	11	8	26	6	12
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	2	-17	6	2	7	6	-18	-29	-18	-11	-4	-18
4	Mean	56	52	51	70	47	61	55	53	42	74	46	72
100	SD	18	11	11	25	9	20	8	10	9	40	13	54
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	12	-10	17	23	21	41	-9	-24	-19	5	1	28

[a] - Anova &amp; Dunnett

[a1] - Anova &amp; Dunnett(Log)

Table 7 Summary of Chemistry-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Male		TP	TP	TP	TP	TP	TP	ALB	ALB	ALB	ALB	ALB	ALB
		(g/L)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)
		[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]
		-11	-6	53	87	123	179	-11	-6	53	87	123	179
1	Mean	80.4	79.5	76.5	74.0	72.7	73.3	44.9	44.5	44.1	42.9	42.7	42.9
0	SD	5.6	2.3	6.2	2.8	1.8	2.8	3.0	2.2	2.9	2.1	2.1	1.8
	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	76.3	76.1	73.7	74.7	72.6	71.1	43.7	44.0	43.3	43.3	43.0	42.7
5	SD	3.4	2.5	4.9	3.9	3.9	2.8	4.4	3.4	1.7	1.8	1.8	1.3
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-5.1	-4.3	-3.7	0.9	-0.1	-3.1	-2.7	-1.1	-1.9	0.8	0.8	-0.4
3	Mean	77.7	77.1	74.4	72.6	71.5	72.2	45.1	44.6	44.5	43.0	41.4	43.1
25	SD	2.9	3.0	3.0	4.5	4.4	2.9	1.5	1.8	1.8	2.8	3.1	1.4
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-3.3	-3.1	-2.8	-1.9	-1.7	-1.5	0.4	0.4	0.9	0.1	-3.2	0.6
4	Mean	77.4	79.8	78.6	77.0	76.7	75.7	42.6	44.4	43.7	41.2	42.6	43.2
100	SD	3.4	5.3	2.7	3.6	3.7	3.1	3.3	3.6	2.4	2.2	3.2	1.8
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-3.7	0.3	2.7	4.1	5.5	3.3	-5.2	-0.1	-0.9	-4.0	-0.2	0.7

[a] - Anova &amp; Dunnett



Table 7 Summary of Chemistry-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Male		TBIL	TBIL	TBIL	TBIL	TBIL	TBIL	ALP	ALP	ALP	ALP	ALP	ALP
		( $\mu\text{mol/L}$ )	( $\mu\text{mol/L}$ )	( $\mu\text{mol/L}$ )	( $\mu\text{mol/L}$ )	( $\mu\text{mol/L}$ )	( $\mu\text{mol/L}$ )	(U/L)	(U/L)	(U/L)	(U/L)	(U/L)	(U/L)
		[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]
		-11	-6	53	87	123	179	-11	-6	53	87	123	179
1	Mean	7.93	4.35	4.41	5.18	5.27	4.98	627	564	744	869	853	838
0	SD	2.02	0.74	1.16	1.61	2.41	1.17	217	153	183	216	138	148
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	10.67	6.99**	5.86	6.08	7.48	7.01	588	532	640	729	703	686
5	SD	2.69	1.99	0.72	0.74	1.78	1.47	206	185	204	208	144	165
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	34.52	60.70	32.84	17.35	41.86	40.65	-6	-6	-14	-16	-18	-18
3	Mean	7.51	4.99	4.51	6.42	4.91	4.64	562	518	663	723	646	607
25	SD	2.11	1.09	0.57	2.66	0.58	1.59	128	120	140	170	127	70
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-5.32	14.59	2.23	23.88	-6.80	-6.79	-10	-8	-11	-17	-24	-28
4	Mean	7.70	4.77	5.51	6.46	6.87	7.32	481	456	540	667	677	649
100	SD	1.15	0.66	1.60	1.93	2.03	2.54	126	95	151	198	214	172
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-2.94	9.61	24.94	24.75	26.46	46.87	-23	-19	-27	-23	-21	-23

[a] - Anova & Dunnett: \*\* =  $p \leq 0.01$

Table 7 Summary of Chemistry-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Male		GGT	GGT	GGT	GGT	GGT	GGT	sGLU	sGLU	sGLU	sGLU	sGLU	sGLU
		(U/L)	(U/L)	(U/L)	(U/L)	(U/L)	(U/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)
		[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]
		-11	-6	53	87	123	179	-11	-6	53	87	123	179
1	Mean	75	70	88	94	105	96	3.08	4.74	3.72	3.33	3.35	3.43
0	SD	22	19	30	31	32	35	0.48	0.81	0.39	0.66	0.45	0.62
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	76	70	80	87	96	87	2.81	4.07	3.59	3.40	3.20	3.34
5	SD	26	23	31	35	37	33	0.39	0.87	0.37	0.48	0.25	0.28
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	2	0	-9	-7	-9	-10	-8.66	-14.03	-3.41	2.21	-4.33	-2.72
3	Mean	78	71	83	85	85	77	2.88	4.09	3.64	3.10	3.21	3.38
25	SD	34	30	31	34	28	21	0.35	0.64	0.36	0.65	0.44	0.68
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	5	0	-5	-9	-19	-20	-6.44	-13.72	-2.11	-6.67	-4.03	-1.56
4	Mean	55	55	62	61	70	64	2.70	4.01	3.43	2.88	3.05	3.51
100	SD	12	11	18	16	15	14	0.32	0.61	0.35	0.18	0.20	0.32
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-26	-22	-29	-35	-34	-34	-12.45	-15.41	-7.89	-13.43	-8.76	2.48

[a] - Anova &amp; Dunnett

Table 7 Summary of Chemistry-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Male		UREA	UREA	UREA	UREA	UREA	UREA	CRE	CRE	CRE	CRE	CRE	CRE
		(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(µmol/L)	(µmol/L)	(µmol/L)	(µmol/L)	(µmol/L)	(µmol/L)
		[a]	[a1]	[a1]	[a]	[a1]	[a1]	[a1]	[a1]	[a1]	[a1]	[a1]	[a1]
		-11	-6	53	87	123	179	-11	-6	53	87	123	179
1	Mean	7.42	5.96	6.65	6.91	7.32	6.99	62	57	60	60	61	62
0	SD	0.73	0.99	0.98	0.57	1.55	0.93	6	5	6	7	9	5
	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	8.03	6.14	7.49	7.35	8.19	8.01	66	62	64	64	69	68
5	SD	2.09	1.19	1.48	1.13	0.96	1.40	16	15	16	12	16	15
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	8.32	3.11	12.69	6.39	11.93	14.59	6	8	6	6	13	9
3	Mean	6.96	5.45	6.19	6.22	6.75	6.06	63	59	61	59	64	64
25	SD	0.52	0.87	0.95	1.01	0.64	1.14	8	7	6	5	6	8
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-6.20	-8.54	-6.90	-9.96	-7.79	-13.42	1	4	2	-2	6	3
4	Mean	7.25	5.15	7.05	7.16	7.95	7.54	61	59	61	61	61	61
100	SD	0.85	0.67	0.95	0.31	1.03	1.21	9	9	10	12	11	12
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-2.25	-13.49	6.07	3.62	8.56	7.77	-1	3	2	1	1	-2

[a] - Kruskal-Wallis & Dunnett on Ranks

[a1] - Anova & Dunnett

Table 7 Summary of Chemistry-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Male		Ca	Ca	Ca	Ca	Ca	Ca	P	P	P	P	P	P
		(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)
		[a]	[a1]	[a]	[a1]	[a1]	[a]	[a1]	[a1]	[a1]	[a1]	[a1]	[a1]
		-11	-6	53	87	123	179	-11	-6	53	87	123	179
1	Mean	2.43	2.57	2.64	2.51	2.46	2.43	2.11	1.89	2.24	2.24	2.19	2.23
0	SD	0.06	0.11	0.15	0.10	0.07	0.06	0.30	0.21	0.36	0.31	0.40	0.13
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	2.41	2.64	2.60	2.55	2.43	2.40	2.15	2.15	2.23	2.31	2.23	2.26
5	SD	0.10	0.13	0.09	0.10	0.10	0.11	0.19	0.24	0.18	0.35	0.20	0.21
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-0.69	2.66	-1.64	1.80	-1.42	-1.58	2.22	13.73	-0.37	3.20	1.98	1.57
3	Mean	2.41	2.58	2.62	2.49	2.46	2.45	2.23	2.00	2.12	2.25	2.13	2.25
25	SD	0.06	0.05	0.05	0.07	0.08	0.05	0.49	0.37	0.44	0.34	0.35	0.34
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-0.48	0.13	-0.63	-0.60	-0.07	0.48	6.01	5.37	-5.36	0.30	-2.52	0.97
4	Mean	2.35	2.60	2.53	2.42	2.37	2.36	2.10	1.99	2.17	2.29	2.25	2.34
100	SD	0.13	0.13	0.10	0.06	0.13	0.03	0.32	0.31	0.45	0.43	0.30	0.29
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-3.23	1.23	-4.17	-3.39	-3.65	-3.22	-0.24	5.02	-3.05	2.16	3.05	5.32

[a] - Kruskal-Wallis &amp; Dunnett on Ranks

[a1] - Anova &amp; Dunnett

Table 7 Summary of Chemistry-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Male		TCHO	TCHO	TCHO	TCHO	TCHO	TCHO	TG	TG	TG	TG	TG	TG
		(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)
		[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a1]	[a]	[a]	[a]
		-11	-6	53	87	123	179	-11	-6	53	87	123	179
1	Mean	3.41	2.98	3.60	3.41	3.55	3.41	0.45	0.30	0.46	0.48	0.46	0.41
0	SD	0.68	0.39	0.87	0.77	0.66	0.63	0.09	0.05	0.13	0.08	0.15	0.10
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	3.87	3.84	3.97	3.98	4.07	3.76	0.61	0.36	0.54	0.47	0.62*	0.47
5	SD	0.88	0.70	0.62	0.50	0.78	0.90	0.21	0.08	0.12	0.12	0.09	0.08
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	13.38	28.66	10.43	16.66	14.50	10.31	37.31	17.58	18.98	-1.39	34.55	14.98
3	Mean	3.77	3.66	3.79	3.49	3.36	3.39	0.52	0.31	0.45	0.46	0.56	0.45
25	SD	0.71	0.79	0.47	0.57	0.51	0.35	0.13	0.06	0.05	0.07	0.08	0.12
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	10.45	22.63	5.38	2.39	-5.54	-0.68	16.42	1.10	-0.73	-4.86	22.55	8.50
4	Mean	3.45	3.26	3.60	3.38	3.34	3.13	0.54	0.28	0.49	0.42	0.46	0.42
100	SD	0.90	0.74	0.49	0.55	0.40	0.34	0.09	0.03	0.03	0.08	0.06	0.06
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	1.07	9.22	0.14	-0.83	-5.96	-8.11	20.90	-8.79	7.30	-12.85	-0.73	2.02

[a] - Anova & Dunnett: \* =  $p \leq 0.05$ 

[a1] - Kruskal-Wallis &amp; Dunnett on Ranks

Table 7 Summary of Chemistry-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Male		K	K	K	K	K	K	Na	Na	Na	Na	Na	Na
		(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)
		[a]	[a]	[a]	[a]	[a]	[a]	[a1]	[a]	[a]	[a1]	[a]	[a]
		-11	-6	53	87	123	179	-11	-6	53	87	123	179
1	Mean	4.3	4.7	4.9	4.6	4.9	4.6	149	151	146	147	145	145
0	SD	0.4	0.7	0.8	0.6	0.7	0.8	3	5	4	3	3	2
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	4.4	5.0	4.8	5.2	4.4	4.4	148	150	145	148	145	144
5	SD	0.4	0.4	0.5	0.7	0.4	0.4	1	2	3	1	2	1
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	2.3	5.3	-0.3	12.8	-11.2	-5.1	-1	-1	-1	0	0	-1
3	Mean	4.5	4.7	4.9	4.8	4.6	4.6	148	151	146	147	145	145
25	SD	0.5	0.5	0.5	0.8	0.5	0.7	1	2	3	1	3	1
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	4.7	-0.4	0.7	4.7	-5.4	0.0	-1	0	0	0	0	0
4	Mean	4.4	5.1	4.7	5.1	4.7	4.8	146 *	151	146	148	144	144
100	SD	0.7	0.8	0.6	1.2	0.4	1.0	1	4	1	2	1	2
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	2.7	8.1	-3.4	10.9	-4.8	5.5	-2	0	0	0	0	-1

[a] - Anova &amp; Dunnett

[a1] - Kruskal-Wallis & Dunnett on Ranks: \* =  $p \leq 0.05$

Table 7 Summary of Chemistry-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Male		Cl	Cl	Cl	Cl	Cl	Cl	GLB	GLB	GLB	GLB	GLB	GLB
		(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)
		[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]
		-11	-6	53	87	123	179	-11	-6	53	87	123	179
1	Mean	104	106	103	103	104	104	35.5	35.1	32.4	31.1	30.0	30.4
0	SD	1	3	2	1	2	3	3.1	2.6	3.8	1.7	1.7	1.7
	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	104	106	102	103	101 *	103	32.6	32.2	30.5	31.5	29.6	28.4
5	SD	1	1	2	2	2	1	3.4	2.7	4.0	3.7	3.6	2.7
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	0	0	-1	0	-3	-1	-8.1	-8.2	-6.1	1.2	-1.4	-6.8
3	Mean	104	107	104	104	102	103	32.6	32.4	29.9	29.7	30.1	29.1
25	SD	2	2	1	2	2	1	2.2	2.3	2.0	2.0	3.9	1.8
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	0	0	1	1	-2	0	-8.0	-7.5	-7.8	-4.6	0.5	-4.4
4	Mean	103	106	101	105	101 *	103	34.8	35.4	34.9	35.8*	34.1	32.5
100	SD	1	3	1	2	1	2	2.6	3.1	1.4	4.0	2.1	1.5
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-1	-1	-2	1	-3	-1	-1.7	0.9	7.5	15.2	13.6	6.8

[a] - Anova &amp; Dunnett: \* = p ≤ 0.05

Table 7 Summary of Chemistry-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Male		A/G	A/G	A/G	A/G	A/G	A/G	CK	CK	CK	CK	CK	CK
		[a]	[a]	[a]	[a]	[a]	[a1]	(U/L)	(U/L)	(U/L)	(U/L)	(U/L)	(U/L)
								[a]	[a2]	[a2]	[a]	[a2]	[a2]
		-11	-6	53	87	123	179	-11	-6	53	87	123	179
1	Mean	1.27	1.28	1.37	1.38	1.43	1.41	499	386	378	992	223	653
0	SD	0.08	0.13	0.11	0.10	0.14	0.09	475	294	173	1541	52	454
	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	1.36	1.38	1.44	1.39	1.48	1.52	481	302	509	1240	369	308
5	SD	0.23	0.20	0.18	0.19	0.19	0.17	478	66	648	1677	190	198
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	7.11	8.14	5.25	0.68	3.13	7.55	-4	-22	35	25	65	-53
3	Mean	1.39	1.38	1.49	1.45	1.39	1.49*	288	200	218	844	249	223
25	SD	0.10	0.11	0.11	0.06	0.20	0.07	202	52	73	1278	154	86
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	9.12	8.33	9.18	4.75	-2.65	5.18	-42	-48	-42	-15	12	-66
4	Mean	1.23	1.26	1.26	1.16*	1.26	1.33	349	268	253	1830	560	1035
100	SD	0.16	0.14	0.09	0.16	0.13	0.05	160	121	40	3490	637	1903
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-3.16	-1.06	-8.18	-15.81	-12.23	-5.81	-30	-31	-33	84	151	58

[a] - Anova & Dunnett: \* = p ≤ 0.05

[a1] - Kruskal-Wallis & Dunnett on Ranks: \* = p ≤ 0.05

[a2] - Anova & Dunnett(Log)



Table 7 Summary of Chemistry-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Female		ALT	ALT	ALT	ALT	ALT	ALT	AST	AST	AST	AST	AST	AST
		(U/L)	(U/L)	(U/L)	(U/L)	(U/L)	(U/L)	(U/L)	(U/L)	(U/L)	(U/L)	(U/L)	(U/L)
		[a]	[a]	[a]	[a]	[a1]	[a]	[a]	[a]	[a]	[a]	[a]	[a1]
		-12	-7	52	86	122	178	-12	-7	52	86	122	178
1	Mean	54	57	52	57	50	48	57	61	50	90	51	56
0	SD	18	15	6	9	15	8	15	21	9	18	13	19
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	50	57	49	64	75	48	52	57	44	92	55	65
5	SD	11	14	10	17	72	11	16	21	8	37	31	33
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-7	0	-5	12	51	1	-9	-6	-13	2	7	15
3	Mean	48	57	43	50	37	45	62	66	58	75	41	50
25	SD	20	23	10	17	12	13	18	22	32	31	7	17
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-10	0	-17	-12	-26	-5	8	9	15	-17	-19	-11
4	Mean	58	54	60	60	57	61	45	48	41	59	38	48
100	SD	16	9	15	14	19	19	11	21	12	12	9	12
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	9	-4	16	5	14	28	-22	-20	-18	-34	-25	-15

[a] - Anova &amp; Dunnett

[a1] - Anova &amp; Dunnett(Log)

Table 7 Summary of Chemistry-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Female		TP	TP	TP	TP	TP	TP	ALB	ALB	ALB	ALB	ALB	ALB
		(g/L)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)
		[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]
		-12	-7	52	86	122	178	-12	-7	52	86	122	178
1	Mean	80.6	80.5	78.5	76.8	76.5	75.9	43.8	44.5	44.4	43.3	43.0	43.2
0	SD	2.7	2.5	4.8	3.9	2.4	5.8	2.5	2.5	2.3	2.0	1.9	2.1
	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	80.9	80.8	77.9	76.0	76.7	75.2	41.7	42.8	42.8	42.0	40.0	42.1
5	SD	4.1	1.8	5.0	1.8	5.5	3.1	2.2	1.7	2.7	1.7	4.6	1.4
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	0.4	0.4	-0.7	-1.0	0.3	-0.9	-4.8	-3.9	-3.7	-3.1	-6.8	-2.5
3	Mean	79.3	79.4	77.1	73.9	76.4	75.1	43.0	44.1	43.4	41.2	42.2	42.3
25	SD	3.5	3.7	2.3	3.7	2.3	3.4	2.2	2.7	2.3	1.5	2.1	1.4
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-1.6	-1.3	-1.7	-3.8	-0.2	-1.1	-1.9	-0.9	-2.2	-4.9	-1.7	-2.1
4	Mean	74.8*	76.2	75.4	75.1	76.8	74.8	42.1	42.9	42.7	41.5	42.9	42.9
100	SD	4.3	4.3	3.5	3.7	3.3	6.0	2.5	2.2	1.5	1.1	1.8	2.1
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-7.4	-5.2	-3.9	-2.1	0.4	-1.5	-4.0	-3.6	-3.8	-4.1	-0.3	-0.8

[a] - Anova &amp; Dunnett: \* = p ≤ 0.05

Table 7 Summary of Chemistry-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Female		TBIL	TBIL	TBIL	TBIL	TBIL	TBIL	ALP	ALP	ALP	ALP	ALP	ALP
		(µmol/L)	(µmol/L)	(µmol/L)	(µmol/L)	(µmol/L)	(µmol/L)	(U/L)	(U/L)	(U/L)	(U/L)	(U/L)	(U/L)
		[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]
		-12	-7	52	86	122	178	-12	-7	52	86	122	178
1	Mean	4.61	5.07	4.72	5.01	4.61	5.08	423	436	450	488	434	438
0	SD	1.50	1.85	2.18	2.19	1.93	2.49	122	129	109	116	126	139
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	4.10	4.43	4.60	4.93	6.70	4.70	437	436	538	611	550	558
5	SD	0.46	0.56	1.28	1.28	4.55	1.10	61	47	64	50	44	37
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-11.06	-12.53	-2.61	-1.63	45.46	-7.49	3	0	20	25	27	27
3	Mean	4.97	5.33	4.26	5.55	5.28	4.51	474	468	517	553	488	494
25	SD	1.07	1.02	1.24	1.75	2.17	1.70	131	143	151	147	143	137
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	7.84	5.16	-9.81	10.78	14.73	-11.07	12	7	15	13	13	13
4	Mean	4.16	4.89	4.55	4.86	5.16	5.12	454	461	419	467	455	446
100	SD	2.09	1.58	1.74	1.59	1.82	1.47	121	118	82	102	121	108
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-9.79	-3.62	-3.60	-2.93	12.12	0.85	7	6	-7	-4	5	2

[a] - Anova & Dunnett

Table 7 Summary of Chemistry-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Female		GGT	GGT	GGT	GGT	GGT	GGT	sGLU	sGLU	sGLU	sGLU	sGLU	sGLU
		(U/L)	(U/L)	(U/L)	(U/L)	(U/L)	(U/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)
		[a]	[a]	[a1]	[a]	[a1]	[a1]	[a2]	[a2]	[a2]	[a2]	[a2]	[a2]
		-12	-7	52	86	122	178	-12	-7	52	86	122	178
1	Mean	52	52	51	52	53	51	3.46	3.76	3.84	3.23	3.96	3.76
0	SD	5	5	7	7	6	7	0.97	0.49	0.95	0.67	0.79	0.94
	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	74	74	80	78	79	76	3.34	3.68	3.39	2.91	3.39	3.04
5	SD	31	31	35	31	22	27	0.34	0.44	0.45	0.31	0.42	0.64
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	43	43	57	51	49	50	-3.33	-2.17	-11.60	-9.87	-14.52	-19.31
3	Mean	44	45	45	44	46	46	2.89	3.69	3.47	2.66	3.23	3.12
25	SD	9	11	11	9	10	10	0.76	0.58	0.26	0.21	0.46	0.54
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-14	-13	-11	-15	-13	-10	-16.40	-1.82	-9.51	-17.56	-18.52	-17.05
4	Mean	69	65	64	64	67	62	3.51	3.31	3.55	3.34	3.36	3.31
100	SD	29	28	23	23	21	21	0.98	0.66	0.73	1.06	0.67	1.17
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	33	26	25	24	26	22	1.64	-11.96	-7.47	3.56	-15.11	-11.96

[a] - Kruskal-Wallis &amp; Dunnett on Ranks

[a1] - Anova &amp; Dunnett(Log)

[a2] - Anova &amp; Dunnett

Table 7 Summary of Chemistry-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Female		UREA	UREA	UREA	UREA	UREA	UREA	CRE	CRE	CRE	CRE	CRE	CRE
		(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	( $\mu$ mol/L)	( $\mu$ mol/L)	( $\mu$ mol/L)	( $\mu$ mol/L)	( $\mu$ mol/L)	( $\mu$ mol/L)
		[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]
		-12	-7	52	86	122	178	-12	-7	52	86	122	178
1	Mean	6.18	5.65	6.32	7.09	6.85	6.90	54	58	58	59	61	60
0	SD	1.06	0.79	0.46	1.33	0.87	1.64	6	6	10	9	6	8
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	5.90	5.10	6.64	7.01	7.29	7.17	56	59	62	63	69	66
5	SD	1.21	1.13	0.57	1.78	0.57	1.03	7	8	7	5	10	12
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-4.56	-9.68	5.14	-1.06	6.52	3.99	5	1	7	7	12	10
3	Mean	6.68	5.28	6.28	6.65	6.47	6.62	56	61	60	59	60	59
25	SD	1.65	0.74	0.75	1.00	0.65	1.13	5	4	8	7	6	5
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	8.09	-6.61	-0.55	-6.19	-5.55	-4.04	5	5	3	0	-2	-1
4	Mean	6.08	5.64	6.63	6.56	7.81	7.30	54	58	59	59	65	62
100	SD	2.08	1.42	1.12	1.50	1.74	1.37	7	8	7	8	11	10
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-1.62	-0.21	4.93	-7.48	14.00	5.85	0	-1	2	0	5	4

[a] - Anova &amp; Dunnett

Table 7 Summary of Chemistry-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Female		Ca	Ca	Ca	Ca	Ca	Ca	P	P	P	P	P	P
		(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)
		[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a1]	[a1]	[a]
		-12	-7	52	86	122	178	-12	-7	52	86	122	178
1	Mean	2.56	2.75	2.65	2.52	2.53	2.51	1.83	1.95	1.93	1.82	1.94	1.91
0	SD	0.10	0.30	0.08	0.10	0.10	0.16	0.26	0.17	0.10	0.11	0.07	0.18
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	2.51	2.62	2.55	2.48	2.44	2.44	1.73	1.82	1.96	1.68	1.85	2.03
5	SD	0.09	0.06	0.11	0.06	0.11	0.06	0.23	0.12	0.18	0.20	0.26	0.24
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-2.02	-4.79	-3.84	-1.59	-3.50	-2.92	-5.29	-6.68	1.38	-7.61	-4.72	6.27
3	Mean	2.49	2.77	2.59	2.45	2.45	2.43	1.79	2.02	2.03	1.82	1.97	2.04
25	SD	0.08	0.26	0.13	0.08	0.12	0.10	0.18	0.09	0.32	0.17	0.15	0.11
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-2.87	0.85	-2.20	-2.91	-3.23	-3.12	-2.28	3.85	5.35	0.00	1.54	6.45
4	Mean	2.48	2.62	2.57	2.48	2.47	2.44	1.71	1.90	1.79	1.75	1.90	1.98
100	SD	0.13	0.12	0.09	0.13	0.13	0.20	0.24	0.23	0.22	0.31	0.36	0.30
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-2.93	-4.85	-3.14	-1.59	-2.18	-2.92	-6.75	-2.57	-7.25	-3.49	-2.49	3.66

[a] - Anova &amp; Dunnett

[a1] - Kruskal-Wallis &amp; Dunnett on Ranks

Table 7 Summary of Chemistry-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Female		TCHO	TCHO	TCHO	TCHO	TCHO	TCHO	TG	TG	TG	TG	TG	TG
		(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)
		[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]
		-12	-7	52	86	122	178	-12	-7	52	86	122	178
1	Mean	3.66	3.43	4.01	3.81	4.12	3.89	0.43	0.39	0.59	0.62	0.62	0.52
0	SD	0.92	0.80	0.65	0.83	0.70	0.78	0.06	0.08	0.15	0.16	0.12	0.15
	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	3.90	3.49	3.86	3.60	4.48	3.69	0.39	0.32	0.46	0.45	0.63	0.40
5	SD	0.54	0.82	0.73	0.69	1.41	0.64	0.10	0.05	0.14	0.08	0.37	0.15
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	6.70	1.60	-3.66	-5.56	8.86	-5.31	-9.30	-19.49	-22.82	-26.83	0.80	-23.00
3	Mean	3.38	3.32	3.59	3.52	3.85	3.62	0.41	0.34	0.46	0.40*	0.45	0.37
25	SD	0.97	0.92	0.99	1.09	1.22	1.17	0.15	0.19	0.13	0.09	0.17	0.11
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-7.66	-3.30	-10.56	-7.57	-6.52	-6.98	-4.65	-12.71	-23.10	-34.96	-27.35	-29.71
4	Mean	3.42	3.31	3.57	3.38	3.59	3.41	0.38	0.39	0.48	0.42*	0.52	0.49
100	SD	0.68	0.85	0.59	0.55	0.51	0.63	0.11	0.09	0.12	0.15	0.14	0.12
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-6.34	-3.69	-10.93	-11.24	-12.95	-12.37	-10.85	-1.69	-18.59	-31.71	-16.35	-6.71

[a] - Anova &amp; Dunnett: \* = p ≤ 0.05

Table 7 Summary of Chemistry-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Female		K	K	K	K	K	K	Na	Na	Na	Na	Na	Na
		(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)
		[a]	[a1]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]
		-12	-7	52	86	122	178	-12	-7	52	86	122	178
1	Mean	5.0	5.0	5.1	4.9	4.9	5.0	149	152	147	149	145	147
0	SD	0.7	0.3	0.5	0.5	0.3	0.8	3	1	4	1	1	4
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	4.6	4.7	4.7	4.7	4.4	4.7	149	152	148	149	146	146
5	SD	0.5	0.2	0.5	0.4	0.6	0.4	2	2	4	1	2	2
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-9.3	-6.0	-8.8	-4.1	-10.2	-6.0	0	0	0	0	1	-1
3	Mean	4.3	5.3	5.1	4.6	4.9	4.6	149	154	147	149	146	146
25	SD	0.3	0.8	0.4	0.5	0.4	0.4	1	3	4	3	3	1
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-14.0	5.6	-1.0	-5.4	-0.3	-7.3	0	1	0	0	1	0
4	Mean	4.8	4.8	4.7	4.7	4.5	4.7	151	152	147	147	147	147
100	SD	0.4	0.6	0.3	0.6	0.4	0.6	3	3	3	4	3	5
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-5.3	-4.0	-7.5	-5.1	-8.5	-7.0	1	0	0	-1	1	0

[a] - Anova & Dunnett

[a1] - Kruskal-Wallis & Dunnett on Ranks



Table 7 Summary of Chemistry-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Female		Cl	Cl	Cl	Cl	Cl	Cl	GLB	GLB	GLB	GLB	GLB	GLB
		(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)
		[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]
		-12	-7	52	86	122	178	-12	-7	52	86	122	178
1	Mean	104	107	104	106	102	104	36.8	36.0	34.1	33.5	33.6	32.7
0	SD	1	2	3	2	3	2	2.8	2.7	4.3	3.9	3.9	5.7
	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	104	107	104	106	102	103	39.2	38.0	35.2	34.1	36.7	33.1
5	SD	3	2	1	2	2	0	3.4	2.3	2.6	1.2	1.3	2.0
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	1	0	0	0	0	-1	6.6	5.7	3.2	1.8	9.3	1.2
3	Mean	104	108	104	107	103	104	36.3	35.3	33.7	32.7	34.2	32.8
25	SD	2	2	2	2	2	2	3.4	2.7	2.4	4.1	3.0	3.4
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	0	1	0	1	0	0	-1.2	-1.8	-1.2	-2.2	1.9	0.2
4	Mean	106	108	104	105	103	104	32.5	33.4	32.7	33.6	34.0	31.9
100	SD	2	2	2	1	2	2	2.8	2.8	2.6	2.6	2.0	4.4
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	3	0	0	-1	0	0	-11.5	-7.2	-4.1	0.3	1.2	-2.5

[a] - Anova &amp; Dunnett

Table 7 Summary of Chemistry-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Female		A/G	A/G	A/G	A/G	A/G	A/G	CK	CK	CK	CK	CK	CK
		[a]	[a]	[a]	[a1]	[a]	[a1]	(U/L)	(U/L)	(U/L)	(U/L)	(U/L)	(U/L)
								[a]	[a]	[a2]	[a]	[a]	[a1]
		-12	-7	52	86	122	178	-12	-7	52	86	122	178
1	Mean	1.20	1.24	1.32	1.31	1.30	1.35	318	259	382	568	401	215
0	SD	0.13	0.14	0.17	0.16	0.19	0.22	135	100	311	187	445	51
	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	1.07	1.13	1.22	1.23	1.09	1.28	403	362	263	973	406	1602
5	SD	0.10	0.10	0.06	0.07	0.11	0.06	230	174	83	486	159	2067
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-10.77	-9.31	-7.72	-5.80	-16.05	-5.71	27	40	-31	71	1	645
3	Mean	1.20	1.25	1.30	1.28	1.25	1.30	301	418	1129	566	260	301
25	SD	0.15	0.13	0.14	0.18	0.15	0.15	138	271	2081	403	116	206
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-0.36	0.73	-1.71	-2.45	-4.08	-3.59	-5	62	195	0	-35	40
4	Mean	1.30	1.29	1.31	1.24	1.26	1.36	365	410	467	648	291	920
100	SD	0.10	0.09	0.10	0.06	0.06	0.15	80	250	366	200	100	1026
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	8.26	3.62	-0.47	-5.22	-2.62	0.59	15	58	22	14	-28	328

[a] - Anova & Dunnett  
 [a1] - Kruskal-Wallis & Dunnett on Ranks  
 [a2] - Anova & Dunnett(Log)

Table 7 Summary of Chemistry-Recovery Phase

Day: 209 Relative to Start Date

Sex: Female		ALT	AST	TP	ALB	TBIL	ALP	GGT	sGLU	UREA	CRE	Ca	P
		(U/L)	(U/L)	(g/L)	(g/L)	( $\mu$ mol/L)	(U/L)	(U/L)	(mmol/L)	(mmol/L)	( $\mu$ mol/L)	(mmol/L)	(mmol/L)
1	Mean	44	38	79.9	47.2	4.31	473	54	4.08	8.34	61	2.72	1.93
0	SD	6	8	1.6	4.3	0.76	21	8	0.39	2.97	6	0.24	0.26
	N	2	2	2	2	2	2	2	2	2	2	2	2
2	Mean	41	36	75.5	44.2	4.84	548	90	3.00	6.74	59	2.56	1.74
5	SD	17	11	1.5	1.1	1.39	51	40	0.25	1.15	6	0.04	0.08
	N	2	2	2	2	2	2	2	2	2	2	2	2
	%Diff	-6	-4	-5.6	-6.3	12.43	16	68	-26.50	-19.24	-4	-5.88	-9.61
3	Mean	51	40	74.8	43.1	5.48	572	42	2.99	6.80	62	2.54	1.89
25	SD	1	8	3.0	0.3	0.30	27	17	0.21	0.06	11	0.09	0.12
	N	2	2	2	2	2	2	2	2	2	2	2	2
	%Diff	16	5	-6.4	-8.6	27.18	21	-21	-26.75	-18.53	1	-6.80	-2.08
4	Mean	58	34	71.7	43.2	5.49	485	50	2.58	8.84	55	2.47	2.18
100	SD	8	5	3.5	1.5	0.47	59	24	0.62	0.64	6	0.22	0.12
	N	2	2	2	2	2	2	2	2	2	2	2	2
	%Diff	32	-11	-10.3	-8.5	27.53	3	-7	-36.69	5.94	-10	-9.38	12.99

Table 7 Summary of Chemistry-Recovery Phase (Cont'd)

Day: 209 Relative to Start Date

Sex: Female		TCHO	TG	K	Na	Cl	GLB	A/G	CK
		(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(g/L)		(U/L)
1	Mean	4.19	0.55	5.4	150	106	32.8	1.45	386
0	SD	0.43	0.18	1.0	7	3	2.8	0.25	163
mg/kg/dose	N	2	2	2	2	2	2	2	2
2	Mean	3.66	0.55	4.4	149	103	31.3	1.41	857
5	SD	0.62	0.04	0.2	4	0	0.4	0.02	824
mg/kg/dose	N	2	2	2	2	2	2	2	2
	%Diff	-12.66	0.92	-19.4	-1	-3	-4.6	-2.49	122
3	Mean	3.39	0.37	5.1	148	107	31.7	1.37	253
25	SD	1.69	0.00	0.6	1	1	3.3	0.15	7
mg/kg/dose	N	2	2	2	2	2	2	2	2
	%Diff	-19.12	-32.11	-5.6	-2	0	-3.4	-5.56	-34
4	Mean	3.80	0.68	4.4	147	105	28.6	1.51	320
100	SD	0.24	0.03	0.4	1	1	2.1	0.06	97
mg/kg/dose	N	2	2	2	2	2	2	2	2
	%Diff	-9.20	24.77	-18.5	-2	-1	-12.8	4.35	-17

Table 7 Summary of Chemistry-Recovery Phase (Cont'd)

Day: 210 Relative to Start Date

Sex: Male		ALT	AST	TP	ALB	TBIL	ALP	GGT	sGLU	UREA	CRE	Ca	P
		(U/L)	(U/L)	(g/L)	(g/L)	( $\mu$ mol/L)	(U/L)	(U/L)	(mmol/L)	(mmol/L)	( $\mu$ mol/L)	(mmol/L)	(mmol/L)
1	Mean	45	51	70.7	42.7	3.84	788	87	3.53	6.90	55	2.49	2.15
	SD	10	2	2.5	0.4	2.03	237	18	0.74	0.11	5	0.04	0.33
	N	2	2	2	2	2	2	2	2	2	2	2	2
0	mg/kg/dose												
	Mean	52	72	69.7	42.8	6.24	909	65	3.65	6.79	59	2.52	2.30
	SD	8	41	5.6	0.4	0.96	325	10	0.35	0.08	16	0.09	0.33
	N	2	2	2	2	2	2	2	2	2	2	2	2
2	%Diff	14	43	-1.4	0.2	62.71	15	-25	3.55	-1.67	7	1.00	7.23
	Mean	47	34	74.5	45.4	4.01	772	71	3.51	6.62	68	2.52	2.31
	SD	17	7	5.3	4.9	0.13	7	17	1.17	0.44	11	0.05	0.01
3	mg/kg/dose												
	N	2	2	2	2	2	2	2	2	2	2	2	2
	%Diff	4	-33	5.4	6.2	4.56	-2	-18	-0.43	-4.06	25	1.00	7.69
4	Mean	56	50	76.6	46.0	6.55	911	79	3.27	7.75	56	2.46	2.14
	SD	4	5	6.6	1.8	0.50	336	1	0.42	0.97	10	0.08	0.39
	N	2	2	2	2	2	2	2	2	2	2	2	2
100	mg/kg/dose												
	%Diff	23	-2	8.4	7.7	70.66	16	-9	-7.23	12.25	3	-1.20	-0.47

Table 7 Summary of Chemistry-Recovery Phase (Cont'd)

Day: 210 Relative to Start Date

Sex: Male		TCHO	TG	K	Na	Cl	GLB	A/G	CK
		(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(mmol/L)	(g/L)		(U/L)
1	Mean	2.89	0.25	4.5	149	107	28.0	1.53	1189
0	SD	0.26	0.07	0.1	3	1	2.1	0.10	469
mg/kg/dose	N	2	2	2	2	2	2	2	2
2	Mean	3.48	0.63	4.6	147	104	26.9	1.62	2535
5	SD	0.37	0.02	0.2	1	1	5.2	0.30	3260
mg/kg/dose	N	2	2	2	2	2	2	2	2
	%Diff	20.45	150.00	2.2	-1	-2	-3.9	5.96	113
3	Mean	3.67	0.48	5.2	147	105	29.1	1.56	627
25	SD	0.89	0.08	0.7	1	1	0.4	0.14	648
mg/kg/dose	N	2	2	2	2	2	2	2	2
	%Diff	27.21	90.00	16.9	-1	-2	4.1	1.70	-47
4	Mean	3.45	0.62	4.6	145	102	30.6	1.52	513
100	SD	0.49	0.18	0.3	1	1	4.8	0.18	180
mg/kg/dose	N	2	2	2	2	2	2	2	2
	%Diff	19.41	146.00	3.4	-3	-4	9.5	-0.92	-57

**Table 8      Summary of Urinalysis**

Table 8 Summary of Urinalysis

Key Page

**Measurement Descriptions**

Headings Used

pH  
SG  
Volume

Description

Urine pH  
Urine Specific Gravity  
Volume



Table 8 Summary of Urinalysis-Pretest and Dosing Phase

Day(s) Relative to Start Date

Sex: Male		pH	pH	pH	pH	pH	SG	SG	SG	SG	SG	Volume (mL) [a]	Volume (mL) [a]
		-11	53	87	123	179	-11	53	87	123	179	-11	53
1	Mean	6.2	7.2	7.1	6.8	6.9	1.013	1.014	1.015	1.012	1.015	19	17
0	SD	1.3	0.9	0.6	1.3	0.6	0.007	0.003	0.005	0.005	0.003	5	6
	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	6.5	7.6	7.3	6.8	7.1	1.018	1.021	1.019	1.015	1.016	14	17
5	SD	0.8	0.6	0.5	0.9	0.7	0.010	0.004	0.007	0.005	0.009	7	8
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	5.4	5.8	3.5	0.0	2.4	0.510	0.674	0.427	0.280	0.016	-26	-3
3	Mean	5.8	7.0	6.6	7.2	7.0	1.019	1.015	1.016	1.013	1.012	16	19
25	SD	1.0	0.4	0.9	0.9	0.8	0.008	0.008	0.009	0.006	0.007	6	6
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-6.8	-2.3	-7.1	6.2	1.2	0.592	0.132	0.148	0.033	-0.312	-17	7
4	Mean	5.9	6.8	7.0	6.7	6.3	1.012	1.008	1.009	1.012	1.011	21	18
100	SD	0.9	0.4	0.9	0.7	0.6	0.009	0.006	0.007	0.005	0.007	10	11
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-4.1	-4.7	-1.2	-1.2	-8.4	-0.082	-0.559	-0.608	-0.033	-0.443	9	5

[a] - Anova & Dunnett

Table 8 Summary of Urinalysis-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Male		Volume	Volume	Volume
		(mL)	(mL)	(mL)
		[a]	[a]	[a]
		87	123	179
1	Mean	24	18	19
0	SD	9	3	8
mg/kg/dose	N	6	6	6
2	Mean	19	13	18
5	SD	3	6	7
mg/kg/dose	N	6	6	6
	%Diff	-19	-29	-5
3	Mean	20	13	16
25	SD	10	5	5
mg/kg/dose	N	6	6	6
	%Diff	-15	-29	-19
4	Mean	28	17	16
100	SD	12	7	7
mg/kg/dose	N	6	6	6
	%Diff	18	-6	-20

[a] - Anova &amp; Dunnett

Table 8 Summary of Urinalysis-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Female		pH	pH	pH	pH	pH	SG	SG	SG	SG	SG	Volume (mL) [a]	Volume (mL) [a1]
		-12	52	86	122	178	-12	52	86	122	178	-12	52
1	Mean	7.0	7.3	7.1	7.1	6.8	1.015	1.012	1.020	1.013	1.011	19	22
0	SD	0.7	0.6	1.0	0.7	1.0	0.008	0.004	0.006	0.006	0.005	12	5
	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	7.2	7.5	7.4	6.7	7.0	1.015	1.013	1.021	1.014	1.015	18	19
5	SD	0.7	0.6	0.7	0.4	0.8	0.007	0.008	0.006	0.006	0.004	6	11
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	2.4	2.3	4.7	-5.9	3.7	0.033	0.082	0.131	0.033	0.379	-5	-15
3	Mean	6.9	7.1	6.8	6.9	6.9	1.018	1.014	1.016	1.013	1.015	24	18
25	SD	0.9	0.7	1.0	1.1	1.1	0.008	0.008	0.007	0.005	0.003	14	2
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-1.2	-3.4	-3.5	-2.4	2.5	0.263	0.132	-0.343	-0.066	0.379	25	-17
4	Mean	7.4	7.4	7.0	6.8	6.7	1.016	1.017	1.016	1.018	1.010	20	16
100	SD	0.4	0.6	1.1	0.9	0.9	0.010	0.008	0.008	0.010	0.007	5	6
	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	6.0	1.1	-1.2	-4.7	-1.2	0.115	0.428	-0.409	0.461	-0.082	5	-26

[a] - Anova &amp; Dunnett

[a1] - Kruskal-Wallis &amp; Dunnett on Ranks

Table 8 Summary of Urinalysis-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Female		Volume	Volume	Volume
		(mL)	(mL)	(mL)
		[a]	[a]	[a1]
		86	122	178
1	Mean	22	18	22
0	SD	2	5	11
mg/kg/dose	N	6	6	6
2	Mean	18	15	17
5	SD	4	6	5
mg/kg/dose	N	6	6	6
	%Diff	-16	-16	-23
3	Mean	20	16	20
25	SD	3	3	3
mg/kg/dose	N	6	6	6
	%Diff	-9	-13	-11
4	Mean	17	13	13
100	SD	6	8	5
mg/kg/dose	N	6	6	6
	%Diff	-19	-28	-42

[a] - Kruskal-Wallis &amp; Dunnett on Ranks

[a1] - Anova &amp; Dunnett

Table 8 Summary of Urinalysis-Recovery Phase

Day: 209 Relative to Start Date

Sex: Female		pH	SG	Volume (mL)
1	Mean	7.3	1.017	30
0	SD	0.4	0.013	11
mg/kg/dose	N	2	2	2
2	Mean	7.8	1.018	40
5	SD	0.4	0.004	1
mg/kg/dose	N	2	2	2
	%Diff	6.9	0.098	36
3	Mean	7.3	1.010	44
25	SD	0.4	0.014	12
mg/kg/dose	N	2	2	2
	%Diff	0.0	-0.639	47
4	Mean	7.0	1.012	55
100	SD	0.0	0.014	41
mg/kg/dose	N	2	2	2
	%Diff	-3.4	-0.443	86

Table 8 Summary of Urinalysis-Recovery Phase (Cont'd)

Day: 210 Relative to Start Date

Sex: Male		pH	SG	Volume (mL)
1	Mean	7.8	1.014	50
0	SD	0.4	0.005	23
mg/kg/dose	N	2	2	2
2	Mean	7.5	1.018	37
5	SD	1.4	0.008	5
mg/kg/dose	N	2	2	2
	%Diff	-3.2	0.444	-27
3	Mean	6.8	1.018	12
25	SD	1.8	0.004	11
mg/kg/dose	N	2	2	2
	%Diff	-12.9	0.444	-76
4	Mean	6.5	1.009	43
100	SD	0.7	0.011	41
mg/kg/dose	N	2	2	2
	%Diff	-16.1	-0.444	-14

**Table 9      Summary of Immunoglobulin and Complement**

Table 9 Summary of Immunoglobulin and Complement

Key Page

**Measurement Descriptions**

<u>Headings Used</u>	<u>Description</u>
C3c	Complement C3c
C4	Complement C4
IgG	Immunoglobulin G
IgA	Immunoglobulin A
IgM	Immunoglobulin M



Table 9 Summary of Immunoglobulin and Complement-Pretest and Dosing Phase

Day(s) Relative to Start Date

Sex: Male		C3c	C3c	C3c	C3c	C4	C4	C4	C4	IgG	IgG	IgG	IgG
		(g/L)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)
		[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a1]	[a]	[a]	[a]	[a]
		-6	1	88	178	-6	1	88	178	-6	1	88	178
1	Mean	1.32	1.21	1.17	1.06	0.18	0.18	0.18	0.18	9.69	9.28	8.31	9.57
0	SD	0.20	0.11	0.09	0.11	0.04	0.05	0.03	0.06	1.08	0.93	1.07	1.29
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	1.23	1.17	1.16	0.97	0.17	0.16	0.20	0.16	8.90	8.07	8.23	9.14
5	SD	0.24	0.15	0.17	0.11	0.07	0.07	0.09	0.06	1.29	1.57	1.32	1.11
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-6.70	-3.57	-1.28	-8.68	-8.33	-9.43	10.38	-7.55	-8.07	-13.06	-0.98	-4.56
3	Mean	1.23	1.10	1.07	1.01	0.20	0.19	0.21	0.19	8.29	8.20	8.33	9.57
25	SD	0.16	0.09	0.10	0.11	0.08	0.07	0.10	0.09	1.35	1.20	0.88	0.91
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-7.08	-9.48	-8.53	-4.73	12.96	4.72	17.92	5.66	-14.40	-11.66	0.20	0.00
4	Mean	1.38	1.21	1.10	0.94	0.22	0.20	0.19	0.15	9.76	11.10	12.43***	13.13***
100	SD	0.26	0.15	0.08	0.08	0.06	0.06	0.06	0.04	1.50	1.64	1.53	1.50
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	4.55	0.00	-6.40	-11.04	19.44	12.26	5.66	-13.21	0.77	19.61	49.46	37.19

[a] - Anova & Dunnett: \*\*\* =  $p \leq 0.001$ 

[a1] - Kruskal-Wallis &amp; Dunnett on Ranks

Table 9 Summary of Immunoglobulin and Complement-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Male		IgA	IgA	IgA	IgA	IgM	IgM	IgM	IgM
		(g/L)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)
		[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]
		-6	1	88	178	-6	1	88	178
1	Mean	2.11	1.94	1.72	1.72	1.00	0.86	0.72	0.71
0	SD	0.79	0.77	0.58	0.57	0.41	0.32	0.31	0.34
mg/kg/dose	N	6	6	6	6	6	6	6	6
2	Mean	1.45	1.30	1.43	1.52	0.94	0.82	0.69	0.66
5	SD	0.60	0.54	0.57	0.58	0.49	0.37	0.33	0.31
mg/kg/dose	N	6	6	6	6	6	6	6	6
	%Diff	-31.39	-32.73	-17.04	-11.53	-5.19	-4.45	-3.93	-6.60
3	Mean	1.66	1.49	1.46	1.57	1.07	1.00	0.94	0.83
25	SD	0.52	0.52	0.49	0.31	0.62	0.61	0.61	0.50
mg/kg/dose	N	6	6	6	6	6	6	6	6
	%Diff	-21.69	-23.17	-15.49	-8.82	7.20	15.47	29.56	16.98
4	Mean	1.97	1.77	1.75	1.60	0.92	0.83	0.77	0.70
100	SD	0.63	0.56	0.55	0.45	0.14	0.20	0.26	0.20
mg/kg/dose	N	6	6	6	6	6	6	6	6
	%Diff	-8.86	-8.79	1.65	-6.88	-8.04	-3.48	7.16	-1.65

[a] - Anova &amp; Dunnett

Table 9 Summary of Immunoglobulin and Complement-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Female		C3c	C3c	C3c	C3c	C4	C4	C4	C4	IgG	IgG	IgG	IgG
		(g/L)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)
		[a]	[a]	[a1]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]
		-7	1	87	177	-7	1	87	177	-7	1	87	177
1	Mean	1.24	1.21	1.11	0.98	0.20	0.20	0.19	0.15	10.66	9.72	9.62	11.54
0	SD	0.15	0.18	0.17	0.20	0.04	0.07	0.04	0.03	2.67	3.55	2.68	3.68
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
2	Mean	1.30	1.20	1.06	0.96	0.20	0.20	0.19	0.17	12.47	12.45	11.19	13.44
5	SD	0.20	0.11	0.06	0.13	0.05	0.05	0.03	0.07	1.41	2.14	1.29	1.73
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	4.70	-0.69	-4.07	-2.04	-0.84	-3.31	-1.75	12.22	16.91	27.99	16.25	16.45
3	Mean	1.18	1.06	1.01	0.95	0.20	0.19	0.20	0.19	10.63	10.39	9.97	12.36
25	SD	0.21	0.14	0.05	0.14	0.05	0.08	0.05	0.04	1.63	1.64	1.45	1.27
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-5.11	-12.28	-8.45	-2.90	0.84	-4.96	5.26	27.78	-0.31	6.89	3.64	7.11
4	Mean	1.20	1.08	0.99	0.89	0.24	0.22	0.19	0.17	8.82	10.18	10.59	12.88
100	SD	0.09	0.09	0.06	0.09	0.06	0.06	0.03	0.05	1.80	1.52	1.24	2.07
mg/kg/dose	N	6	6	6	6	6	6	6	6	6	6	6	6
	%Diff	-3.63	-10.90	-10.86	-8.86	20.17	9.92	-0.88	13.33	-17.24	4.66	10.08	11.61

[a] - Anova & Dunnett

[a1] - Kruskal-Wallis & Dunnett on Ranks

Table 9 Summary of Immunoglobulin and Complement-Pretest and Dosing Phase (Cont'd)

Day(s) Relative to Start Date

Sex: Female		IgA	IgA	IgA	IgA	IgM	IgM	IgM	IgM
		(g/L)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)	(g/L)
		[a]	[a]	[a]	[a]	[a]	[a]	[a]	[a]
		-7	1	87	177	-7	1	87	177
1	Mean	1.41	1.30	1.49	1.48	1.27	1.15	1.01	1.06
0	SD	0.62	0.55	0.57	0.53	0.54	0.47	0.42	0.40
mg/kg/dose	N	6	6	6	6	6	6	6	6
2	Mean	1.51	1.50	1.60	1.53	1.19	1.08	0.92	0.98
5	SD	0.62	0.57	0.63	0.72	0.58	0.58	0.41	0.35
mg/kg/dose	N	6	6	6	6	6	6	6	6
	%Diff	6.73	15.55	7.25	3.73	-6.41	-5.68	-8.62	-7.40
3	Mean	1.78	1.62	1.88	1.83	1.30	1.09	1.08	1.14
25	SD	0.62	0.53	1.04	0.92	0.39	0.33	0.35	0.34
mg/kg/dose	N	6	6	6	6	6	6	6	6
	%Diff	26.21	24.55	26.00	24.07	2.09	-5.24	6.97	7.40
4	Mean	1.46	1.40	1.47	1.36	1.02	0.88	0.91	0.88
100	SD	0.65	0.66	0.52	0.40	0.39	0.31	0.44	0.46
mg/kg/dose	N	6	6	6	6	6	6	6	6
	%Diff	3.54	7.97	-1.56	-8.14	-19.76	-23.14	-9.12	-19.21

[a] - Anova &amp; Dunnett

Table 9 Summary of Immunoglobulin and Complement-Recovery Phase

Day: 210 Relative to Start Date

Sex: Female		C3c	C4	IgG	IgA	IgM
		(g/L)	(g/L)	(g/L)	(g/L)	(g/L)
1	Mean	0.96	0.12	12.60	1.34	0.92
0	SD	0.12	0.01	3.85	0.54	0.43
mg/kg/dose	N	2	2	2	2	2
2	Mean	0.88	0.17	14.13	1.14	0.83
5	SD	0.04	0.04	0.58	0.84	0.06
mg/kg/dose	N	2	2	2	2	2
	%Diff	-7.85	41.67	12.14	-14.98	-9.84
3	Mean	0.86	0.13	11.44	2.29	1.38
25	SD	0.13	0.00	1.97	1.20	0.14
mg/kg/dose	N	2	2	2	2	2
	%Diff	-9.95	8.33	-8.21	71.16	50.82
4	Mean	0.83	0.17	9.03	1.50	1.09
100	SD	0.01	0.02	0.06	0.08	0.59
mg/kg/dose	N	2	2	2	2	2
	%Diff	-13.61	37.50	-28.37	11.99	19.13

Table 9 Summary of Immunoglobulin and Complement-Recovery Phase (Cont'd)

Day: 211 Relative to Start Date

Sex: Male		C3c	C4	IgG	IgA	IgM
		(g/L)	(g/L)	(g/L)	(g/L)	(g/L)
1	Mean	0.99	0.16	9.06	1.69	0.85
0	SD	0.06	0.08	1.95	0.93	0.40
mg/kg/dose	N	2	2	2	2	2
2	Mean	0.85	0.13	9.65	1.22	0.47
5	SD	0.05	0.05	2.29	0.69	0.35
mg/kg/dose	N	2	2	2	2	2
	%Diff	-14.21	-21.88	6.51	-28.11	-45.29
3	Mean	0.95	0.25	8.88	1.38	0.64
25	SD	0.11	0.03	0.56	0.10	0.32
mg/kg/dose	N	2	2	2	2	2
	%Diff	-4.06	56.25	-2.04	-18.34	-25.29
4	Mean	0.90	0.14	10.42	1.77	0.53
100	SD	0.01	0.04	1.80	0.39	0.16
mg/kg/dose	N	2	2	2	2	2
	%Diff	-8.63	-12.50	14.96	4.44	-38.24

**Table 1 Summary of Immunophenotyping Results-Monkey Blood (CD45+CD3+, Total T Cells)**

Animal No.	Subpopulation percent (%) for T/B Panel (Male)				
	Pretest	Day 1 2~4h	Day 88	Day 178	Day 211
1001	65.86	54.33	63.33	68.76	NA
1002	62.88	56.50	64.79	66.92	NA
1003	63.69	62.57	55.87	63.28	NA
1004	63.57	59.57	66.70	74.52	NA
1005	63.37	59.09	61.06	67.57	66.49
1006	34.54	29.52	45.37	54.71	57.69
<b>Mean</b>	<b>58.99</b>	<b>53.60</b>	<b>59.52</b>	<b>65.96</b>	<b>62.09</b>
<b>SD</b>	<b>12.02</b>	<b>12.12</b>	<b>7.87</b>	<b>6.61</b>	<b>6.22</b>
2001	53.42	52.01	65.20	73.68	NA
2002	68.86	54.31	57.89	69.52	NA
2003	56.25	55.54	61.83	71.19	NA
2004	57.28	42.99	60.66	74.13	NA
2005	59.04	53.47	60.48	71.69	70.00
2006	54.76	51.27	68.28	76.05	79.22
<b>Mean</b>	<b>58.27</b>	<b>51.60</b>	<b>62.39</b>	<b>72.71</b>	<b>74.61</b>
<b>SD</b>	<b>5.54</b>	<b>4.49</b>	<b>3.74</b>	<b>2.35</b>	<b>6.52</b>
3001	60.71	55.96	56.68	66.83	NA
3002	56.79	55.23	58.29	66.37	NA
3003	71.53	65.61	72.66	74.19	NA
3004	74.36	71.01	74.71	82.21	NA
3005	55.79	48.15	52.26	55.75	58.11
3006	68.69	64.83	72.75	78.14	77.54
<b>Mean</b>	<b>64.65</b>	<b>60.13</b>	<b>64.56</b>	<b>70.58</b>	<b>67.83</b>
<b>SD</b>	<b>7.92</b>	<b>8.43</b>	<b>9.88</b>	<b>9.56</b>	<b>13.74</b>
4001	59.71	55.17	69.21	71.41	NA
4002	70.61	64.81	64.92	68.34	NA
4003	48.66	43.16	49.26	55.35	NA
4004	61.84	50.29	67.47	75.62	NA
4005	57.10	50.70	68.00	80.73	79.90
4006	60.83	57.38	72.62	79.00	72.86
<b>Mean</b>	<b>59.79</b>	<b>53.59</b>	<b>65.25</b>	<b>71.74</b>	<b>76.38</b>
<b>SD</b>	<b>7.12</b>	<b>7.36</b>	<b>8.23</b>	<b>9.26</b>	<b>4.98</b>

**Table 2 Summary of Immunophenotyping Results-Monkey Blood  
(CD45+CD3+CD4+CD8-, Helper T Cells)**

Animal No.	Subpopulation percent (%) for T/B Panel (Male)				
	Pretest	Day 1 2~4h	Day 88	Day 178	Day 211
1001	22.23	26.66	25.10	30.80	NA
1002	42.81	37.48	43.48	43.90	NA
1003	43.52	42.20	35.53	38.70	NA
1004	34.51	33.25	36.85	41.26	NA
1005	32.40	30.28	30.31	35.03	31.02
1006	20.80	18.35	28.84	35.53	37.71
<b>Mean</b>	<b>32.71</b>	<b>31.37</b>	<b>33.35</b>	<b>37.54</b>	<b>34.37</b>
<b>SD</b>	<b>9.74</b>	<b>8.38</b>	<b>6.59</b>	<b>4.72</b>	<b>4.73</b>
2001	25.68	27.17	38.40	43.80	NA
2002	43.02	32.03	31.96	41.47	NA
2003	26.97	25.48	26.10	33.24	NA
2004	32.55	24.46	33.87	44.37	NA
2005	26.96	26.05	29.67	35.08	34.06
2006	34.64	33.73	37.76	39.75	43.32
<b>Mean</b>	<b>31.64</b>	<b>28.15</b>	<b>32.96</b>	<b>39.62</b>	<b>38.69</b>
<b>SD</b>	<b>6.61</b>	<b>3.80</b>	<b>4.74</b>	<b>4.58</b>	<b>6.55</b>
3001	37.67	31.82	32.12	38.96	NA
3002	34.60	32.36	33.12	39.73	NA
3003	38.50	38.30	39.50	39.90	NA
3004	41.68	41.25	40.68	47.08	NA
3005	29.99	26.32	29.65	28.77	32.38
3006	42.52	39.27	43.82	47.90	46.90
<b>Mean</b>	<b>37.49</b>	<b>34.89</b>	<b>36.48</b>	<b>40.39</b>	<b>39.64</b>
<b>SD</b>	<b>4.66</b>	<b>5.67</b>	<b>5.61</b>	<b>6.91</b>	<b>10.27</b>
4001	29.70	30.26	36.32	33.20	NA
4002	36.43	33.76	31.05	32.49	NA
4003	19.57	18.44	21.68	21.91	NA
4004	31.09	26.19	30.12	31.96	NA
4005	32.84	28.17	42.42	55.07	54.86
4006	35.52	33.73	40.93	42.77	40.68
<b>Mean</b>	<b>30.86</b>	<b>28.43</b>	<b>33.75</b>	<b>36.23</b>	<b>47.77</b>
<b>SD</b>	<b>6.09</b>	<b>5.74</b>	<b>7.74</b>	<b>11.35</b>	<b>10.03</b>



**Table 3 Summary of Immunophenotyping Results-Monkey Blood (CD45+CD3+CD4-CD8+, Cytotoxic T Cells)**

Animal No.	Subpopulation percent (%) for T/B Panel (Male)				
	Pretest	Day 1 2~4h	Day 88	Day 178	Day 211
1001	39.95	23.50	33.66	33.56	NA
1002	15.87	14.75	16.50	17.67	NA
1003	16.16	16.93	15.79	20.52	NA
1004	24.84	22.38	24.26	28.18	NA
1005	26.82	25.18	26.35	27.75	30.94
1006	11.12	8.28	13.18	15.95	16.94
<b>Mean</b>	<b>22.46</b>	<b>18.50</b>	<b>21.62</b>	<b>23.94</b>	<b>23.94</b>
<b>SD</b>	<b>10.41</b>	<b>6.41</b>	<b>7.82</b>	<b>6.93</b>	<b>9.90</b>
2001	23.28	20.52	22.71	26.56	NA
2002	22.56	18.67	22.23	24.44	NA
2003	25.58	26.55	29.39	31.51	NA
2004	18.83	13.79	20.77	23.55	NA
2005	27.51	23.69	26.32	32.90	32.52
2006	15.87	13.55	24.91	30.00	29.12
<b>Mean</b>	<b>22.27</b>	<b>19.46</b>	<b>24.39</b>	<b>28.16</b>	<b>30.82</b>
<b>SD</b>	<b>4.30</b>	<b>5.23</b>	<b>3.15</b>	<b>3.87</b>	<b>2.40</b>
3001	18.56	19.21	19.38	22.55	NA
3002	18.85	19.87	21.24	22.63	NA
3003	29.23	23.72	29.40	30.75	NA
3004	28.41	24.63	30.02	30.46	NA
3005	20.91	17.36	18.67	22.32	22.03
3006	21.13	20.25	24.58	26.23	26.80
<b>Mean</b>	<b>22.85</b>	<b>20.84</b>	<b>23.88</b>	<b>25.82</b>	<b>24.42</b>
<b>SD</b>	<b>4.75</b>	<b>2.78</b>	<b>4.96</b>	<b>3.98</b>	<b>3.37</b>
4001	25.34	20.43	29.07	33.98	NA
4002	29.61	26.67	29.82	31.55	NA
4003	25.45	20.39	22.77	27.86	NA
4004	22.25	17.01	28.81	35.88	NA
4005	19.81	16.88	20.68	20.98	21.02
4006	22.13	20.10	28.84	33.55	29.44
<b>Mean</b>	<b>24.10</b>	<b>20.25</b>	<b>26.67</b>	<b>30.63</b>	<b>25.23</b>
<b>SD</b>	<b>3.45</b>	<b>3.55</b>	<b>3.90</b>	<b>5.46</b>	<b>5.95</b>

**Table 4 Summary of Immunophenotyping Results-Monkey Blood  
(CD45+CD3-CD20+, B Cells)**

Animal No.	Subpopulation percent (%) for T/B Panel (Male)				
	Pretest	Day 1 2~4h	Day 88	Day 178	Day 211
1001	20.76	34.61	21.87	16.39	NA
1002	22.23	29.73	24.97	21.66	NA
1003	25.90	31.49	34.03	28.21	NA
1004	31.24	33.25	23.10	18.92	NA
1005	24.31	25.98	27.79	23.54	24.27
1006	38.72	55.28	26.57	21.43	26.85
<b>Mean</b>	<b>27.19</b>	<b>35.06</b>	<b>26.39</b>	<b>21.69</b>	<b>25.56</b>
<b>SD</b>	<b>6.71</b>	<b>10.35</b>	<b>4.33</b>	<b>4.04</b>	<b>1.82</b>
2001	30.14	37.06	27.19	17.61	NA
2002	26.37	37.89	35.17	23.62	NA
2003	32.27	32.92	17.44	15.69	NA
2004	28.93	46.89	26.67	17.68	NA
2005	35.15	41.54	33.96	24.19	25.37
2006	37.80	46.04	26.39	16.77	14.18
<b>Mean</b>	<b>31.78</b>	<b>40.39</b>	<b>27.80</b>	<b>19.26</b>	<b>19.78</b>
<b>SD</b>	<b>4.19</b>	<b>5.45</b>	<b>6.38</b>	<b>3.67</b>	<b>7.91</b>
3001	26.64	30.38	31.92	21.30	NA
3002	20.81	27.90	17.81	18.43	NA
3003	19.41	30.20	19.34	19.09	NA
3004	15.74	20.65	15.59	10.86	NA
3005	22.38	33.28	32.31	21.69	25.74
3006	23.32	27.72	17.96	16.90	15.90
<b>Mean</b>	<b>21.38</b>	<b>28.36</b>	<b>22.49</b>	<b>18.05</b>	<b>20.82</b>
<b>SD</b>	<b>3.70</b>	<b>4.28</b>	<b>7.55</b>	<b>3.95</b>	<b>6.96</b>
4001	31.17	39.83	21.15	16.25	NA
4002	20.94	26.52	20.55	15.40	NA
4003	45.76	50.18	47.34	41.93	NA
4004	32.40	44.86	24.95	19.03	NA
4005	34.28	43.78	22.96	13.80	13.91
4006	33.94	38.14	23.09	15.73	23.30
<b>Mean</b>	<b>33.08</b>	<b>40.55</b>	<b>26.67</b>	<b>20.36</b>	<b>18.61</b>
<b>SD</b>	<b>7.93</b>	<b>8.06</b>	<b>10.24</b>	<b>10.71</b>	<b>6.64</b>

**Table 5 Summary of Immunophenotyping Results-Monkey Blood (CD45+CD3+, Total T Cells)**

Animal No.	Subpopulation percent (%) for T/B Panel (Female)				
	Pretest	Day 1 2~4h	Day 88	Day 178	Day 211
1501	58.85	46.12	67.53	63.79	NA
1502	70.24	61.75	71.01	74.49	NA
1503	71.36	69.94	72.24	77.39	NA
1504	64.03	53.01	61.77	63.32	NA
1505	55.22	50.61	55.89	62.53	58.22
1506	74.81	69.00	67.78	63.32	67.47
<b>Mean</b>	<b>65.75</b>	<b>58.41</b>	<b>66.04</b>	<b>67.47</b>	<b>62.85</b>
<b>SD</b>	<b>7.68</b>	<b>9.97</b>	<b>6.16</b>	<b>6.63</b>	<b>6.54</b>
2501	66.67	62.84	67.49	69.78	NA
2502	65.55	53.64	73.41	73.36	NA
2503	60.44	49.13	55.40	62.36	NA
2504	63.69	58.10	67.91	63.48	NA
2505	60.55	46.25	62.99	65.41	65.44
2506	56.24	43.88	52.99	50.78	59.40
<b>Mean</b>	<b>62.19</b>	<b>52.31</b>	<b>63.37</b>	<b>64.20</b>	<b>62.42</b>
<b>SD</b>	<b>3.87</b>	<b>7.27</b>	<b>7.87</b>	<b>7.75</b>	<b>4.27</b>
3501	59.94	54.33	51.08	56.24	NA
3502	71.57	67.43	68.57	64.95	NA
3503	68.78	65.62	68.47	72.46	NA
3504	54.63	53.36	61.10	66.15	NA
3505	57.65	54.83	67.89	73.86	58.06
3506	60.38	54.05	59.48	62.19	68.63
<b>Mean</b>	<b>62.16</b>	<b>58.27</b>	<b>62.77</b>	<b>65.98</b>	<b>63.35</b>
<b>SD</b>	<b>6.60</b>	<b>6.44</b>	<b>6.97</b>	<b>6.55</b>	<b>7.47</b>
4501	51.89	45.08	61.25	60.23	NA
4502	58.94	55.33	60.85	64.94	NA
4503	73.11	75.20	69.81	74.83	NA
4504	65.85	65.47	68.85	73.59	NA
4505	62.28	61.70	53.97	71.98	71.88
4506	73.01	67.96	77.52	82.82	84.25
<b>Mean</b>	<b>64.18</b>	<b>61.79</b>	<b>65.38</b>	<b>71.40</b>	<b>78.07</b>
<b>SD</b>	<b>8.28</b>	<b>10.51</b>	<b>8.33</b>	<b>7.92</b>	<b>8.75</b>

**Table 6 Summary of Immunophenotyping Results-Monkey Blood  
(CD45+CD3+CD4+CD8-, Helper T Cells)**

Animal No.	Subpopulation percent (%) for T/B Panel (Female)				
	Pretest	Day 1 2~4h	Day 88	Day 178	Day 211
1501	32.32	25.33	37.50	35.04	NA
1502	46.83	40.88	44.70	46.76	NA
1503	45.20	47.48	44.09	49.57	NA
1504	30.02	24.13	34.70	36.05	NA
1505	36.52	34.59	35.77	40.41	37.76
1506	39.88	42.25	26.86	28.15	31.40
<b>Mean</b>	<b>38.46</b>	<b>35.78</b>	<b>37.27</b>	<b>39.33</b>	<b>34.58</b>
<b>SD</b>	<b>6.79</b>	<b>9.50</b>	<b>6.62</b>	<b>7.94</b>	<b>4.50</b>
2501	31.42	31.24	31.61	32.94	NA
2502	36.64	33.27	33.04	31.33	NA
2503	36.92	29.90	31.64	37.75	NA
2504	38.63	35.88	41.09	39.00	NA
2505	39.25	30.30	39.10	39.01	39.54
2506	32.59	26.08	29.10	21.27	29.15
<b>Mean</b>	<b>35.91</b>	<b>31.11</b>	<b>34.26</b>	<b>33.55</b>	<b>34.35</b>
<b>SD</b>	<b>3.20</b>	<b>3.31</b>	<b>4.73</b>	<b>6.83</b>	<b>7.35</b>
3501	28.77	28.39	26.41	30.06	NA
3502	45.59	43.37	42.42	42.22	NA
3503	34.96	36.43	37.33	37.33	NA
3504	27.29	28.07	28.93	30.81	NA
3505	39.90	38.54	34.47	48.82	34.27
3506	38.77	35.39	37.98	36.23	40.31
<b>Mean</b>	<b>35.88</b>	<b>35.03</b>	<b>34.59</b>	<b>37.58</b>	<b>37.29</b>
<b>SD</b>	<b>6.99</b>	<b>5.94</b>	<b>5.99</b>	<b>7.10</b>	<b>4.27</b>
4501	30.76	27.58	38.54	35.99	NA
4502	26.28	26.97	24.03	24.47	NA
4503	45.32	49.01	42.13	44.51	NA
4504	37.46	38.58	40.41	41.03	NA
4505	34.16	33.08	33.50	38.17	36.80
4506	46.18	42.30	49.17	49.14	46.54
<b>Mean</b>	<b>36.69</b>	<b>36.25</b>	<b>37.96</b>	<b>38.89</b>	<b>41.67</b>
<b>SD</b>	<b>7.94</b>	<b>8.67</b>	<b>8.52</b>	<b>8.46</b>	<b>6.89</b>

**Table 7 Summary of Immunophenotyping Results-Monkey Blood  
(CD45+CD3+CD4-CD8+, Cytotoxic T Cells)**

Animal No.	Subpopulation percent (%) for T/B Panel (Female)				
	Pretest	Day 1 2~4h	Day 88	Day 178	Day 211
1501	22.57	16.51	25.89	24.33	NA
1502	18.84	15.70	20.60	21.17	NA
1503	23.59	19.63	25.52	24.79	NA
1504	30.27	24.86	23.37	23.84	NA
1505	15.38	12.53	16.39	18.52	16.75
1506	29.35	20.71	35.36	29.92	30.23
<b>Mean</b>	<b>23.33</b>	<b>18.32</b>	<b>24.52</b>	<b>23.76</b>	<b>23.49</b>
<b>SD</b>	<b>5.80</b>	<b>4.33</b>	<b>6.37</b>	<b>3.83</b>	<b>9.53</b>
2501	31.74	27.87	31.71	30.35	NA
2502	26.44	17.73	37.81	38.25	NA
2503	19.85	14.92	19.96	20.00	NA
2504	22.39	19.36	23.89	21.82	NA
2505	17.15	12.05	19.41	21.27	21.40
2506	20.93	15.04	19.17	26.11	26.44
<b>Mean</b>	<b>23.08</b>	<b>17.83</b>	<b>25.33</b>	<b>26.30</b>	<b>23.92</b>
<b>SD</b>	<b>5.23</b>	<b>5.53</b>	<b>7.75</b>	<b>6.99</b>	<b>3.56</b>
3501	26.35	21.11	20.15	21.24	NA
3502	22.02	19.86	22.04	18.75	NA
3503	30.52	25.78	27.47	31.25	NA
3504	24.38	22.28	29.33	32.76	NA
3505	14.77	12.76	30.37	22.47	21.11
3506	18.54	15.03	18.99	23.06	25.46
<b>Mean</b>	<b>22.76</b>	<b>19.47</b>	<b>24.73</b>	<b>24.92</b>	<b>23.29</b>
<b>SD</b>	<b>5.62</b>	<b>4.80</b>	<b>4.93</b>	<b>5.70</b>	<b>3.08</b>
4501	17.32	14.48	19.97	21.46	NA
4502	25.16	21.73	26.94	29.79	NA
4503	22.84	21.19	23.70	25.25	NA
4504	24.18	22.85	24.63	27.62	NA
4505	24.88	25.17	17.07	29.92	31.64
4506	19.59	18.31	22.23	25.08	28.67
<b>Mean</b>	<b>22.33</b>	<b>20.62</b>	<b>22.42</b>	<b>26.52</b>	<b>30.16</b>
<b>SD</b>	<b>3.19</b>	<b>3.75</b>	<b>3.51</b>	<b>3.25</b>	<b>2.10</b>

**Table 8 Summary of Immunophenotyping Results-Monkey Blood  
(CD45+CD3-CD20+, B Cells)**

Animal No.	Subpopulation percent (%) for T/B Panel (Female)				
	Pretest	Day 1 2~4h	Day 88	Day 178	Day 211
1501	28.96	39.90	18.35	16.22	NA
1502	18.34	24.24	15.33	15.66	NA
1503	20.73	19.61	19.41	16.45	NA
1504	22.97	29.85	18.54	14.17	NA
1505	26.42	32.66	29.61	17.99	19.77
1506	18.01	21.94	19.24	32.26	28.94
<b>Mean</b>	<b>22.57</b>	<b>28.03</b>	<b>20.08</b>	<b>18.79</b>	<b>24.36</b>
<b>SD</b>	<b>4.42</b>	<b>7.59</b>	<b>4.90</b>	<b>6.71</b>	<b>6.48</b>
2501	21.59	25.53	18.52	13.72	NA
2502	28.01	34.34	17.78	14.08	NA
2503	29.92	44.34	26.14	22.93	NA
2504	22.80	27.67	15.27	8.99	NA
2505	32.90	43.04	24.11	18.50	20.37
2506	26.88	35.81	28.57	32.76	26.70
<b>Mean</b>	<b>27.02</b>	<b>35.12</b>	<b>21.73</b>	<b>18.50</b>	<b>23.54</b>
<b>SD</b>	<b>4.27</b>	<b>7.70</b>	<b>5.28</b>	<b>8.44</b>	<b>4.48</b>
3501	28.12	37.16	45.26	37.45	NA
3502	18.93	27.91	22.71	32.23	NA
3503	23.20	28.48	21.80	17.35	NA
3504	33.48	37.07	26.55	24.17	NA
3505	32.78	33.26	27.16	11.89	12.77
3506	28.07	34.47	18.53	27.43	22.50
<b>Mean</b>	<b>27.43</b>	<b>33.06</b>	<b>27.00</b>	<b>25.09</b>	<b>17.64</b>
<b>SD</b>	<b>5.59</b>	<b>4.06</b>	<b>9.50</b>	<b>9.43</b>	<b>6.88</b>
4501	41.34	51.03	29.84	31.81	NA
4502	31.28	36.76	24.19	18.84	NA
4503	11.02	14.83	10.02	9.42	NA
4504	22.27	22.83	22.71	17.60	NA
4505	34.63	35.18	34.83	24.13	22.68
4506	24.34	29.97	20.11	13.31	13.33
<b>Mean</b>	<b>27.48</b>	<b>31.77</b>	<b>23.62</b>	<b>19.19</b>	<b>18.01</b>
<b>SD</b>	<b>10.64</b>	<b>12.47</b>	<b>8.52</b>	<b>7.95</b>	<b>6.61</b>

**Table 25 Summary of cytokine results-monkey serum**

Animal No.	Cytokine Conc.(pg/mL), Pretest Male							
	IL-2	IL-5	IL-6	IL-10	IL-13	TNF-a	IFN-r	IL-4
1001	<2.90	<2.70	8.80	<8.36	<2.63	<2.31	<2.67	<1.98
1002	49.99	<2.70	10.52	<8.36	<2.63	<2.31	<2.67	<1.98
1003	<2.90	<2.70	2.83	<8.36	<2.63	<2.31	<2.67	<1.98
1004	<2.90	<2.70	<2.61	<8.36	<2.63	<2.31	<2.67	<1.98
1005	<2.90	<2.70	<2.61	<8.36	<2.63	<2.31	<2.67	<1.98
1006	<2.90	<2.70	<2.61	<8.36	<2.63	<2.31	<2.67	<1.98
Mean	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal
SD	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal
2001	<2.90	<2.70	<2.61	<8.36	<2.63	<2.31	<2.67	<1.98
2002	14.20	<2.70	<2.61	48.43	3.07	3.26	50.09	12.47
2003	<2.90	<2.70	<2.61	79.31	<2.63	6.86	36.05	10.48
2004	<2.90	<2.70	23.86	13.12	<2.63	<2.31	<2.67	<1.98
2005	<2.90	<2.70	<2.61	<8.36	<2.63	<2.31	<2.67	<1.98
2006	<2.90	<2.70	<2.61	<8.36	<2.63	<2.31	<2.67	<1.98
Mean	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal
SD	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal
3001	<2.90	<2.70	10.66	<8.36	<2.63	<2.31	<2.67	<1.98
3002	<2.90	<2.70	<2.61	<8.36	<2.63	<2.31	<2.67	<1.98
3003	<2.90	<2.70	<2.61	<8.36	<2.63	<2.31	<2.67	<1.98
3004	<2.90	<2.70	<2.61	<8.36	<2.63	<2.31	<2.67	<1.98
3005	<2.90	<2.70	<2.61	<8.36	<2.63	<2.31	<2.67	<1.98
3006	<2.90	3.49	9.32	<8.36	<2.63	<2.31	<2.67	<1.98
Mean	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal
SD	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal
4001	<2.90	<2.70	<2.61	<8.36	<2.63	<2.31	<2.67	<1.98
4002	<2.90	<2.70	<2.61	<8.36	<2.63	<2.31	<2.67	<1.98
4003	<2.90	<2.70	<2.61	<8.36	<2.63	<2.31	<2.67	<1.98
4004	<2.90	<2.70	<2.61	<8.36	4.86	<2.31	<2.67	<1.98
4005	<2.90	<2.70	<2.61	<8.36	<2.63	<2.31	<2.67	<1.98
4006	<2.90	<2.70	<2.61	<8.36	<2.63	<2.31	<2.67	<1.98
Mean	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal
SD	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal

NcalN: Curve fitting failed; N/A: Data marked out; ND: Missing original data

**Table 26 Summary of cytokine results-monkey serum**

Cytokine Conc.(pg/mL), Pretest Female								
Animal No.	IL-2	IL-5	IL-6	IL-10	IL-13	TNF-a	IFN-r	IL-4
1501	<2.90	<2.70	8.80	<8.36	<2.63	<2.31	<2.67	<1.98
1502	49.99	<2.70	10.52	<8.36	<2.63	<2.31	<2.67	<1.98
1503	<2.90	<2.70	2.83	<8.36	<2.63	<2.31	<2.67	<1.98
1504	<2.90	<2.70	<2.61	<8.36	<2.63	<2.31	<2.67	<1.98
1505	<2.90	<2.70	<2.61	<8.36	<2.63	<2.31	<2.67	<1.98
1506	<2.90	<2.70	<2.61	<8.36	<2.63	<2.31	<2.67	<1.98
Mean	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal
SD	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal
2501	<2.90	<2.70	<2.61	<8.36	<2.63	<2.31	<2.67	<1.98
2502	14.20	<2.70	<2.61	48.43	3.07	3.26	50.09	12.47
2503	<2.90	<2.70	<2.61	79.31	<2.63	6.86	36.05	10.48
2504	<2.90	<2.70	23.86	13.12	<2.63	<2.31	<2.67	<1.98
2505	<2.90	<2.70	<2.61	<8.36	<2.63	<2.31	<2.67	<1.98
2506	<2.90	<2.70	<2.61	<8.36	<2.63	<2.31	<2.67	<1.98
Mean	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal
SD	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal
3501	<2.90	<2.70	10.66	<8.36	<2.63	<2.31	<2.67	<1.98
3502	<2.90	<2.70	<2.61	<8.36	<2.63	<2.31	<2.67	<1.98
3503	<2.90	<2.70	<2.61	<8.36	<2.63	<2.31	<2.67	<1.98
3504	<2.90	<2.70	<2.61	<8.36	<2.63	<2.31	<2.67	<1.98
3505	<2.90	<2.70	<2.61	<8.36	<2.63	<2.31	<2.67	<1.98
3506	<2.90	3.49	9.32	<8.36	<2.63	<2.31	<2.67	<1.98
Mean	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal
SD	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal
4501	<2.90	<2.70	<2.61	<8.36	<2.63	<2.31	<2.67	<1.98
4502	<2.90	<2.70	<2.61	<8.36	<2.63	<2.31	<2.67	<1.98
4503	<2.90	<2.70	<2.61	<8.36	<2.63	<2.31	<2.67	<1.98
4504	<2.90	<2.70	<2.61	<8.36	4.86	<2.31	<2.67	<1.98
4505	<2.90	<2.70	<2.61	<8.36	<2.63	<2.31	<2.67	<1.98
4506	<2.90	<2.70	<2.61	<8.36	<2.63	<2.31	<2.67	<1.98
Mean	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal
SD	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal	Ncal

NcalN: Curve fitting failed; N/A: Data marked out; ND: Missing original data